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The purpose of this research was to investigate selected methods of mucosal 
immunization for commercial chickens. Induction of mucosal immunity in commercial 
chickens through the use of orally administered subunit vaccines or through 
immunomodulation of the host’s response to live vaccines may be a viable means to 
control enteric infections in commercial poultry. In the present investigations we 
evaluated a means for delivering protein antigen in the drinking water and the use of 
CpG-ODNs, a recently reported mucosal adjuvant, in order to both improve this 
response and to modulate the host’s immune response when vaccinated with field strains 
of Eimeria acervulina and Eimeria tenella. 
In order to evaluate the efficacy of immunizing commercial poultry with subunit 
vaccines through the drinking water we chose the model antigen Bovine Serum Albumin 
(BSA). Chicks were administered BSA via intraperitoneal (I.P.) injection, oral crop 
gavage, or orally through the addition of BSA to the drinking water. These experiments 
demonstrated the efficacy of drinking water administration to induce antibody 
 iv
production in the serum, intestine, and bile. When BSA was co-administered with CpG-
ODNs we observed a modest increase in this response dependent upon dose. 
To evaluate the immunomodulation of the host response to live parasite using 
CpG-ODNs we used three administration models. The first was a single dose of CpG-
ODNs with a trickle immunization regime of Eimeria acervulina. The second was co-
administration of CpG-ODNs with a clinical dose of Eimeria acervulina or tenella. The 
third was pre-administration of CpG-ODNs 24 hours prior to the clinical dose of either 
species. These studies demonstrate that the first and third models were effective in 
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The poultry industry represents one of the most important sectors in all modern 
animal agriculture within in United States. It is considered to be a $22 billion industry 
and employs about 240,000 workers (U.S.D.A., 2004) It is one of the fastest growing 
segments of the animal industry and, as such, involves intensive rearing conditions 
where large numbers of birds, usually flocks with tens of thousands, are raised inside a 
closed house (Sharma, 1999). To control disease conditions under these dense and 
intensive rearing environments, vaccines represent an important and invaluable 
prophylactic and therapeutic strategy for commercial producers (Sharma, 2003). 
Vaccines induce protection by stimulating lymphocytes to produce antibodies or 
cytokines and differentiate into memory cells so that subsequent encounters with the 
same pathogens will be resolved quickly and efficiently (Abbas, 2003; Sharma, 2003).  
The fundamental task of the immune system in such a scenario is to protect the 
host against invading microorganisms or pathogens through a cooperative approach 
involving both innate and adaptive immunity. Innate immune responses are typically 
activated by innate system cells, such as macrophages, heterophils, or dendritic cells, 
which then act in concert to either kill the invading microbe or augment and trigger an 
appropriate adaptive immune response (Abbas, 2003). Because innate immune  
_______________    
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cells lack the highly specific antigen receptors found on T and B cells, they rely on 
surface membrane proteins known as pattern recognition receptors (PRRs). 
PRRs have the ability to detect surface components of microbial pathogens known as 
pathogen associated molecular patterns (PAMPs). PAMPs recognition by PRRs in this 
setting is an indication of a threat to the host in the form of potential infection (Teixeira 
et al., 2002). Such recognition activates appropriate defense pathways in the innate 
system to either remove the pathogen or stimulate the adaptive system to act upon the 
pathogen for its ultimate removal. Cytosine-phosphate-guanosine (CpG) motifs naturally 
present in bacterial DNA represent one of the most recent examples of substances that 
influence adaptive immune responses by activating the innate immune system. CpGs are 
6-8 base nucleotide motifs consisting of an unmethylated CpG dinucleotide that induces 
cells of the innate immune system to increase phagocytosis, pro-inflammatory cytokine 
production, activation of NK cells, and increase nitric oxide generation by macrophages 
(Hemmi et al., 2000; Krieg, 2002).  
The most critical line of defense against pathogens in an organism is the mucosal 
associated lymphoid tissues (MALT), the largest of which, in terms of lymphocyte 
populations, is the gut associated lymphoid tissues (GALT) (Bar-Shira et al., 2003; 
Lillehoj and Trout, 1996; Yun et al., 2000b). This system is considered to be the most 
important with regards to enteric pathogens as it is both the primary route of entry and 
site of infection, as such it is also an ideal route for vaccine administration (Bar-Shira et 
al., 2003). The ability of CpG-oligodeoxynucleotides (ODN) to act as vaccine adjuvants 
has been explored extensively in recent years in mammals but very little research has 
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been conducted along these lines in commercial poultry. Therefore, the objective of this 
investigation was to evaluate the administration of CpG-ODN as an adjuvant to oral 
administration of a protein antigen or to oral administration of live parasite. 
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CHAPTER II 
REVIEW OF LITERATURE 
 
BACKGROUND 
Basic Concepts of Immunology 
The term immunity comes from the Latin word immunitis originating from the 
Roman Empire where it signified freedom from taxes, services, and prosecution (Abbas, 
2003). Historically, immunity has been defined as the condition in which an organism 
can resist disease; however we now know that this resistance to infection also involves a 
response to non-infectious foreign substances. Thus the modern definition of immunity 
has been altered to include the reaction to foreign substances such as microbes, as well 
as macromolecules such as proteins and polysaccharides that don’t necessarily have a 
physiological or pathological consequence (Abbas, 2003). This reaction to foreign 
substances, including the response to vaccines, is mediated by the immune system.  
Taken as a whole, the immune system is the only defense an organism has 
against infectious disease (Lynn et al., 2003). At the most basic level an immune 
response is a response to an antigen. Antigens are molecules, such as proteins or sugars, 
which can react with specific antibodies or antigen receptors on lymphocytes. Antigens 
that can elicit an antibody response by themselves are termed immunogens (Janeway and 
Travers, 1997). A whole host of factors can affect this response including the nature of 
the antigen, how the host is exposed to it, as well as the genetics and general health of 
the host (Abbas, 2003). 
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Innate and adaptive immunity are two integrated but distinct forms of immunity 
which must be able to perform three functions; recognize pathogens, kill pathogens, and 
not damage host cells (Beutler, 2004). Both the innate and adaptive arms of the immune 
system perform these functions, but in very different ways. Specifically they differ in 
how they detect pathogens, respond to pathogens, reaction time, and discrimination of 
self and non-self (Abbas, 2003). The innate immune system detects conserved molecular 
patterns of pathogens through receptors that are fixed in the genome and are expressed 
on cells which are essentially identical. The adaptive immune system uses receptors 
encoded in gene segments and subject to rearrangement that detect details of molecular 
structures and are expressed in a clonal fashion. Likewise, the innate immune system 
responds through expression of co-stimulatory molecules, cytokines, and chemokines, 
while the adaptive immune system responds through clonal expansion or anergy (non-
responsiveness) and the expression of effector cytokines such as IL-2, IL-4 and IFN-γ. 
Innate immunity also responds more quickly than adaptive and, due to evolutionary 
selection, does not react with self-antigens. The discrimination of adaptive immunity, 
however, is done in individual somatic cells and does allow some cross-reactivity 
(Janeway and Medzhitov, 2002).  
Innate Immunity 
Innate immunity is the first line of defense against invading pathogens (Zekarias 
et al., 2002). Physical and chemical barriers, such as skin, feathers, lysozyme, lactoferrin 
and antimicrobial peptides are generally regarded as part of innate immunity as they play 
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an important role in preventing the entrance of pathogens, but will not be extensively 
considered here.  
Once a pathogen has entered an organism the first cells to encounter it are the 
phagocytes. These include macrophages, dendritic cells, and heterophils, all of which 
play crucial roles in inflammation and the initiation of an immune response (Harmon, 
1998; Qureshi, 1998). These cells ingest the pathogen through pinocytosis, phagocytosis, 
or receptor mediated endocytosis (Qureshi, 1998). The recognition of pathogens by the 
innate system is generally done by receptors fixed in the genome called pattern 
recognition receptors (PRRs) (Janeway and Medzhitov, 2002). PRRs recognize pathogen 
associated molecular patterns (PAMPs). PAMPs are characterized by three primary traits 
(1) they are expressed by microbes, but not host cells (2) they show little variation 
among a given class of microorganisms, and (3) they perform some essential function 
for the microbe (Teixeira et al., 2002). In both mammals and birds PRRs can be secreted, 
expressed on the cell-surface, or expressed intracellularly. Secreted PRRs encompasses 
the collectin family of proteins which includes mannose binding lectin (MBL) and 
pulmonary surfactant proteins, the pentraxin family of proteins which includes C-
reactive protein (CRP) and serum amyloid protein (SAP), LPS binding protein (LBP), 
the secreted form of CD14, and C3b (Beutler, 2004; Janeway and Medzhitov, 2002; 
Teixeira et al., 2002). Cell surface PRRs include a number of receptors expressed on 
macrophages and dendritic cells. These include scavenger receptors (SR) such as the 
scavenger receptor type A (SR-A) family which recognizes a broad spectrum of ligands 
including double- stranded RNA (dsRNA), LPS and lipoteichoic acid (LTA) (Peiser et 
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al., 2002). Cell surface PRRs also include the macrophage mannose receptor (MMR), as 
well as some toll-like receptors (TLRs). Those TLR expressed on the cell surface are 
TLR1, which with TLR2 bind bacterial lipopeptides and glycophosphoinositol (GPI) 
anchored proteins from parasites, TLR4, which binds LPS from gram-negative bacteria , 
TLR5, which binds flagellin, and TLR6, which binds lipoteichoic acid (LTA) from 
bacteria and zymosan from fungi (Janeway and Medzhitov, 2002). Intracellularly 
expressed PRRs include the virally induced double-stranded RNA-activated protein 
kinase, as well as some others TLRs. The TLRs expressed intracellularly are TLR3, 
which binds double stranded RNA, TLR7 and TLR8, which bind single stranded RNA, 
and TLR9, which binds unmethylated CpG ODNs from bacteria (Lynn et al., 2003; 
Teixeira et al., 2002).  
The interactions of PAMPs and PRRs have a number of potential outcomes. 
Those that are secreted generally aid in the internalization of the antigen through 
opsonization by antibodies or aid in complement-mediated killing (Beutler, 2004). 
Surface expressed and intracellular PRRs aid in the internalization of the antigen, but 
may also aid with its enzymatic degradation, further processing and presentation through 
the MHC class I or II molecules, and by the induction of co-stimulatory signals resulting 
in the activation of the adaptive immune system by activating naïve T and B cells to 
proliferate and differentiate (Aderem and Underhill, 1999; Janeway and Medzhitov, 





In contrast to innate immunity, adaptive immunity is both slower to respond as 
well as more specific and effective. This effectiveness stems from the fact that adaptive 
immunity involves highly specific receptor-antigen interactions, allowing it to focus on 
specific pathogens, as well as being tailored to deal with pathogens that are both extra 
and intracellular (Erf, 2004). These two categories are referred to as humoral and cell 
mediated responses (Abbas, 2003). Humoral immunity consists of the activation of B 
cells which is responsible for the production of immunoglobulins. Immunoglobulins are 
antibodies and mainly present in serum, or on cell surfaces, egg yolk, bile, and mucosal 
secretions (Abbas, 2003). The specificity of antibodies in birds is generated through 
combinatorial joining of the variable regions during development and, later in life, 
somatic gene conversion. This differs from most mammals where somatic mutation is 
responsible for further diversity (Butler, 1998). Antibodies can react to pathogenic 
organisms in a number of different ways. They can act directly by neutralization, 
preventing the pathogen from attaching to surface receptors of target cells thereby 
inhibiting replication and invasion, or indirectly. Indirect actions include opsonization, 
through attachment to the microbes surface, thereby facilitating their internalization by 
macrophages and phagocytic cells leading to subsequent destruction of pathogen and 
activation of complement by the classical pathway. In this pathway antibodies bind to 
the surface of the pathogen and activates complement proteins, which are bound to 
phagocytes receptors facilitating their phagocytosis and destruction (Abbas, 2003). 
There are three main isotypes of immunoglobulins in chickens: IgA, IgG(Y), and IgM. 
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This differs from mammals in that most mammals have multiple subtypes of IgG as well 
as two other standard types. These other types are IgD, which is expressed during certain 
developmental stages, and IgE, which is involved in allergy and immunity to nematodes. 
(Abbas, 2003; Avery et al., 2004). IgM is found on the surface of most B cells, and is 
usually the antibody that predominates in a primary immune response. Class switching 
of an antibody occurs when IgM producing cells stop producing this isotype and 
“switch” to the production of another isotype like IgG or IgA. The cytokines that 
stimulate the B cells to induce a class switch are IL-4 and IL-5. IgG is the predominant 
immunoglobulin circulating in blood and IgA is the primary antibody involved in 
mucosal immunity (Holmgren et al., 1992; Staeheli et al., 2001). 
Cell mediated immunity involves the activation of T lymphocytes or T cells. T 
cells exist as two different classes of cells; 1) T helper lymphocytes (CD4+ or Th cells), 
which function to secrete cytokines for regulating immune responses, and 2) T cytotoxic 
lymphocytes (CD8+ or Tc), which destroy cells infected with intracellular pathogens 
(Abbas, 2003). T cells recognize antigen through the T-cell receptor (TCR) which binds 
to a small linear portion of the antigen. However, the TCR can only recognize this 
peptide when it is associated with self-MHC, this is termed “MHC-restriction”. The two 
types of T-cells are dependent upon different types of MHC, Th cells recognize antigen 
in the context of MHC class II and Tc cells recognize antigen in the context of MHC 
class I. Expression of the two MHC classes also differs. MHC class I is expressed on all 
nucleated cells, whereas MHC class II is only expressed on antigen presenting cells (Erf, 
2004). 
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Antigen presenting cells, such as dendritic cells, B cells, and macrophages, are 
the cell populations that integrate the innate and adaptive immune systems. In their 
immature form, these cells phagocytose and degrade pathogens and express the degraded 
microbial peptides in major histocompatibility complex (MHC) class I or II molecules 
for presentation to lymphocytes (Abbas, 2003; Janeway and Medzhitov, 2002). After the 
identification of the pathogen, the non-mature antigen presenting cells of the innate 
system control the acute innate host response by phagocytosing and then killing 
the invading microbe with reactive oxygen and nitrogen intermediates (superoxide 
anion, hydrogen peroxide, chloramines and hydroxyl radicals) and proteolytic enzymes 
(Abbas, 2003; Werling and Jungi, 2003). The end product of this microbial recognition 
is the activation of intracellular signaling pathways that initiate maturation of the APC 
resulting in a number of cellular responses. These include production of inflammatory 
and effector cytokines such as TNF-α, IL-1β, IL-12 and type I interferons, up regulation 
of co-stimulatory molecules like CD80 and CD86, and presentation of the antigenic 
peptides through their expression in MHC class I or II molecules for antigen presentation 
to the acquired immune system (Swaggerty et al., 2004; Werling and Jungi, 2003). 
The most important outcome from the activation of naive T cells through the 
presentation of the antigen-MHC complex is the proliferation of the antigen-specific T 
cells and the subsequent differentiation into effector and memory cells (Wagner, 2002). 
The origin of the pathogen will determine the class of MHC molecule used. Any 
extracellular antigen or protein, such as bacteria, parasites, and bacterial toxins, will be 
presented through an MHC class II complex and recognized by a CD4+ T cell. Any 
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antigen or protein with an endogenous origin or presence in the cytosol, such as a virus 
or intracellular bacterium, will be presented through the MHC class I pathway and will 
be recognized by CD8+ T cells. T cells become activated and initiate the production of 
different cytokines that will function in the effector stages of cell mediated immunity. T 
cells will also increase the expression of receptors for different cytokines once activated. 
One of the most important cytokines secreted for proliferation of T cells is IL-2, an 
autocrine cytokine, which acts as a growth factor (Abbas, 2003; Erf, 2004). Dependent 
on the T cell phenotype activated (CD4+ or CD8+) a specific differentiation pathway will 
be followed. CD4+ T cells differentiate into one of two, Th1 or Th2, effector Th cell 
subsets that are defined by different cytokine profiles and the type of effector functions 
they initiate in other cells of the immune system (Erf, 2004). Th1 cells typically secrete 
cytokines such as IL-2, IFNγ, and TNF-α, all of which play important roles in promoting 
the cell mediated immune response. Th2 cells secrete IL-4, IL-5, IL-6, and IL-10 
promoting the humoral immune response (Abbas, 2003; Erf, 2004; Staeheli et al., 2001). 
When CD8+ T cells recognize the antigen presented, they differentiate into cytotoxic 
lymphocytes (CTLs) which have the capacity to lyse and kill cells expressing foreign 
antigen in MHC I molecules through the release of perforins, granzymes, and cytolysins 
(Abbas, 2003). The most important function of the CD4+ effector cells is to activate 
phagocytic cells and lymphocytes. In addition to cytokine signals, other direct molecular 
interactions are also necessary. These costimulators help T lymphocytes to work in 
harmony and include the interactions of CD-2 (on the T-cell) with LFA-3, CD40L with 
CD40, and CD28 with B-7 (Abbas, 2003). 
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B lymphocytes require stimulation similar to T cells in order to proliferate and 
differentiate into antibody producing cells or memory cells (Abbas, 2003). This 
stimulation can come from two sources dependent on the type of B-cell. The first applies 
to conventional B cells, also called the B2 subgroup. This form of stimulation occurs 
when antigen binds to the immunoglobulin on the surface and activation occurs with the 
help of costimulation by antigen-specific Th2 cells through the interaction of CD40 with 
its ligand and the secretion of cytokines (Bernasconi et al., 2002). The second applies to 
the B1 subgroup. This form of stimulation is T-cell independent, occurs in the absence 
of antigen, produces primarily IgM, and is activated through microbialy derived products 
such as LPS or CpG-ODN, which stimulate B cells via TLR4 and TLR9 respectively 
(Bernasconi et al., 2002; Fagarasan and Honjo, 2000).  This second form of stimulation 
may be particularly important in intestinal immunity as many of the IgA producing cells 
in the intestine are derived from the B1 subtype after nonspecific stimulation by T-cells 
(Fagarasan and Honjo, 2000). 
 Cytokines are essential effector molecules of both innate and acquired immunity 
and have been implicated in actions as diverse as mediating precursor cell development 
and inhibition, cellular apoptosis (programmed cell death) and enhanced cell survival, 
tumor rejection and metastasis, pro-inflammatory and anti-inflammatory responses, as 
well as the induction of either protection against infectious diseases or pathogenesis of 
infectious diseases (Kogut, 2000). They are soluble low molecular weight polypeptides 
and glycopeptides produced by different immune cells in order to regulate other cells 
and can be classified as interferons (IFNs), tumor necrosis factors (TNF), interleukins 
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(IL), and chemokines (Staeheli et al., 2001). To date most of the cytokines found in 
mammals have been identified in chickens as well. These include IFNα, IFNβ, IFNγ, IL-
1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, IL-16, IL-17, and IL-18 (Avery et al., 2004; 
Lillehoj et al., 2004; Staeheli et al., 2001). While their functions seem to be conserved 
between mammals and birds, their sequence similarity is not. Sequence similarity 
between mammalian and avian cytokines typically ranges from 30-50% (Hilton et al., 
2002). IFNα and IFNβ, also called type I IFNs, are both expressed at elevated levels in 
response to viral infection, whereas IFNγ, the only type II IFN, is involved in most 
stages of the immune response and inflammation (Kogut, 2000; Staeheli et al., 2001). 
IL-1β primarily induces secretion of pro-inflammatory cytokines such as IL-6 and TNF-
α. Many of the cytokines are also defined as to the type of T helper response they 
promote, Th1 or Th2. Homologues for Th1 cytokines have been identified in the chicken 
and include IFN-γ, IL-2, IL-12, and IL-18 (Davison, 2003; Staeheli et al., 2001). Until 
recently the only Th2 cytokine homologue identified in the chicken was IL-6, which 
induces IL-4 production in mammals and is a regulator of immunoglobulin synthesis 
(Staeheli et al., 2001). Recently, however, a gene cluster encoding IL-3, IL-4, IL-13, and 
GM-CSF was identified in the chicken and a number of Th2 cytokines were cloned 
(Avery et al., 2004). Interestingly the avian homologue for IL-5 was also present in the 
cluster but was a pseudogene. However, another sequence in that same cluster, clone 
KK34, was separately identified and demonstrates many of the features of IL-5 (Avery 
et al., 2004; Koskela et al., 2004). In addition, the presence of a Th1 response in 
chickens has been demonstrated through the use of maleylated proteins, which have been 
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demonstrated to promote a Th1 response in mammals. The promotion of delayed type 
hypersensitivity, induction of IFN-γ, and reduction of antibody response were observed 
when using this method (Vandaveer et al., 2001). However, due to the recent 
identification of Th2 cytokines in chickens, the Th1/Th2 paradigm has not yet been fully 
confirmed.  
It is well established that certain types of immune responses are restricted to 
certain areas of the body. Due to the fact that the vast majority of pathogens gain entry 
into the body through mucosal surfaces, the mucosal associated lymphoid tissues 
(MALT) are one of the most critical lines of defense against pathogens. The MALT can 
also be divided into lymphoid tissues of specific areas such as bronchial (BALT), nasal 
(NALT), and gut associated lymphoid tissue (GALT) (Bar-Shira et al., 2003; Yun et al., 
2000b). Of these, the GALT forms the major component, containing more than half of 
the lymphocytes associated with the MALT (Lillehoj and Lillehoj, 2000).  The GALT 
consists of multiple layers of tissues with the epithelial cells and lymphocytes 
comprising the outer layer above the basement membrane, beneath which is the lamina 
propria (LP), lymphocytes, and the submucosa (Yun et al., 2000b). There are also 
specialized lymphoid organs present in the GALT. In the chicken these include the bursa 
of Fabricius (BF), cecal tonsils (CT), Meckel’s diverticulum, Peyers patches (PP), 
collections of intraepithelial lymphocytes (IELs) such as T-cells and NK cells, and other 
localized or diffuse immune cells throughout the lamina propria (Lillehoj and Trout, 
1996). All of these cells are known to secrete and respond to cytokines forming a bi-
directional communication network that is important for both protective immunity as 
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well as modulation of the immune responses to innocuous antigens such as food antigens 
(Klipper et al., 2000; Yun et al., 2000b). This balance between immunity and tolerance 
becomes very important when vaccination protocols are considered and will be 
addressed in more detail below. 
Vaccination and the Use of Adjuvants 
Well before the mechanisms of immunity and disease resistance were known it 
was observed that recovery from an infectious disease resulted in increased protection 
from re-infection. In practice, early immunization involved purposely exposing a person 
to a pathogen in order to obtain a milder form of the disease, which then would protect 
from more serious sickness. This method was used to protect against smallpox by 
inhaling dried smallpox scabs, a process known as variolation, as early as 1000 AD in 
China, and by the early 18th century in Europe (Levine and Lagos, 2004). In the mid 
1700s Paul Adámi experimentally vaccinated cattle for rinderpest by implanting threads 
impregnated with infected animal saliva (Foss and Murtaugh, 2000).   
The first publicly demonstrated use of a related or modified organism to 
vaccinate against infectious disease was not until 1776 by Edward Jenner (Levine and 
Lagos, 2004). Jenner formalized the practice of inoculating with cowpox, which 
stemmed from the observation that people working with cowpox infected cattle were 
protected from smallpox, as “vaccine inoculation” (Levine and Lagos, 2004). It is 
assumed that Jenner used cowpox, however, the virus used may have actually been 
horsepox (Taylor, 1993). The first modification of bacteria for use as a vaccine was 
described by Louis Pasteur in 1879. A culture of Pasteurella multocida, the etiological 
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agent of Fowl Cholera, was accidentally left at room temperature and, although it failed 
to induce clinical disease, it did cause the birds to be resistant to subsequent challenge 
with virulent bacteria (Levine and Lagos, 2004). This observation established the 
principle of vaccination and was used by Pasteur in the preparation of vaccines for both 
anthrax and rabies. It was also Pasteur who coined the term ‘vaccine’ in honor of 
Jenner’s use of the vaccinia virus (Foss and Murtaugh, 2000).  
To this day, widespread vaccination remains the most successful method in 
controlling and preventing losses in farm animals due to infectious diseases. These 
vaccines consist primarily of live attenuated organisms, killed organisms, and 
inactivated toxin. The use of attenuated vaccines are limited primarily by safety, as 
attenuated forms will occasionally revert to virulence, thus causing the disease one 
intended to prevent. Conversely, killed organisms lack the ability to stimulate strong cell 
mediated immunity (Singh and O'Hagan, 2003).  These issues are being addressed 
through the development of a number of novel types of vaccines. These include, but are 
not limited, to vectored vaccines, subunit vaccines, peptide vaccines, and polynucleotide 
vaccines (Babiuk et al., 1999). Vectored vaccines are attenuated pathogens capable of 
multiplying in the host and containing foreign genes of interest. These can be viruses or 
bacteria that have either been attenuated or are not pathogenic to the animal being 
vaccinated (Pastoret, 1999). Subunit vaccines are defined as containing one or more pure 
or semi-pure antigens. Peptide vaccines are a reduction of subunit vaccines. Instead of 
the entire protein only individual epitopes, sequences recognized by an antibody, are 
used. Polynucleotide vaccines, also called genetic or DNA vaccines, are cDNA 
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sequences which encode for an antigen. These sequences are taken up and expressed by 
host cells, thus enabling the host to expose itself to the antigen (Babiuk et al., 1999). 
These issues are further complicated, in the cases of subunit, peptide, and DNA 
vaccines, by the difficulties in delivering them to mucosal surfaces and the lack of 
immunogenicity of subunit vaccines (Medina and Guzman, 2000). Some of these 
difficulties can be overcome through the use of adjuvants. 
 Adjuvants are compounds which, when combined with an antigen, potentiate the 
immune response by replacing some property of the living pathogen lost through 
attenuation or separation into component parts (Foss and Murtaugh, 2000; Medina and 
Guzman, 2000). Mechanistically the actions of adjuvants can be divided into three 
categories: persistence, location, and context. Persistence refers to increasing the time of 
antigen contact. This replaces pathogen replication and reinfection and is done generally 
by creating a ‘depot’ through emulsions, or in the context of mucosal immunity 
continuous exposure to the antigen or encapsulation. Location refers to where the 
antigen makes contact. This replaces opsonization of some pathogens or the intracellular 
location of viruses and some bacteria and is done generally by intradermal injections, or 
in the context of mucosal immunity the uptake of DNA vaccines and the ‘targeting’ of 
antigen by molecules such as the Cholera toxin-B (CT-B) subunit. Context refers to 
enhancement of immune cells directly through cytokine expression or costimulatory 
molecules. This replaces a pathogens ability to induce cytokines through pathogen 
associated molecular patterns (PAMPs) and can be done generally through the use of 
bacterially derived components such as lipopolysacharide (LPS), or in the context of 
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mucosal immunity through the use of cholera toxin (CT) or unmethylated CpG-ODNs 
(Eriksson and Holmgren, 2002; Foss and Murtaugh, 2000). Adjuvants can be roughly 
divided into two types, vaccine delivery systems and immunostimulatory adjuvants, 
however some are not easily classified. The former group includes emulsions, 
microparticles, immunostimulatory complexes (ISCOMs) and lipsomes. These function 
primarily to direct the antigen to APCs. Immunostimulatory adjuvants function primarily 
to activate APCs and induce cytokines. These include bacterial products such as 
monophosphoryl lipid A (MPL), CpG-ODNs, and saponins as well as the direct 
activation of APCs via expression of recombinant cytokines in vectors (Muir et al., 
2000; Rankin et al., 2002; Singh and O'Hagan, 2003). 
 As the intestinal surfaces of commercial poultry are subject to assault by a 
variety of microorganisms, and the need for mass vaccination necessitates the use of the 
oral route, two strategies will be discussed in more detail and in the context of poultry 
immunization. These are oral immunization with protein antigen and the use of CpG-
ODNs as mucosal adjuvants. 
The primary obstacle to oral immunization with protein antigens, or subunit 
vaccines, is the induction of tolerance. However, even if a response is mounted, it is 
often weak and short-lived. Tolerance induction has been addressed more fully than the 
strength of the response due to the investigation of tolerance mechanisms in both 
mammals and chickens. Oral tolerance is a condition of unresponsiveness of the immune 
system to an orally administered antigen (Miller and Cook, 1994). The avian immune 
system does become tolerant to orally ingested food antigens in a fashion similar to 
 19
mammals, however, tolerance in chickens is developmentally dependent. It is usually 
only induced when the animal is a neonate, usually during the first week of life (0- 10 
days post hatch). After this period fed antigens become immunostimulatory and do not 
induce tolerance. Interestingly, this phenomenon occurring at 10 days of age in the 
chicken coincides with the appearance of the Peyer’s patches (PP), more extensive B and 
T cell colonization, and subsequent cytokine expression at mucosal sites, all of which are 
required for the induction of humoral responses in the mucosa (Bar-Shira et al., 2003; 
Klipper et al., 2001; Miller and Cook, 1994). The ability of an orally administered 
antigen to either induce tolerance or immunity depends not only on the age of the 
animal, but on the frequency, dose and physical presentation of the antigen given. It has 
been shown that solubilized antigen given orally in low concentrations on consecutive 
days induce a robust systemic humoral response. When administered in similar 
concentration and route of administration, but using a dry or pelletized form of antigen, 
tolerance is induced (Klipper et al., 2000,2001). Thus, after the birds become more 
immunologically mature the ability of developing oral tolerance to solubilized antigens 
is lost. A possible explanation for this difference from mammals is the difference in 
evolution. The bird is immediately exposed to food antigens during the period in which 
the immune response is immature and can be tolerized. Since the diet is usually the same 
at later ages there would be no need for continuing tolerance. In the mammal, however, 
the change of diet after weaning exposes it to a completely new set of innocuous food 
antigens at a time when the immune system is almost fully mature (Klipper et al., 2001). 
Additionally it has been demonstrated that the hyper immunization of breeding hens 
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with BSA and the subsequent presence of maternal antigen-specific antibodies in 
progeny inhibit tolerance. These authors suggest this to be mechanisms to describe why 
some pathogens which are exposed to the neonatal chick do not induce tolerance 
(Klipper et al., 2004). 
The discovery of the immunostimulatory actions of bacterial DNA stemmed 
from a series of investigations describing reduction of tumor growth after vaccination 
with bacille Calmette-Guérin (BCG) (Hacker et al., 2002). Later Kreig and co-workers 
demonstrated both direct and indirect stimulation of B cells, stimulation of NK cells to 
secrete IFN-γ, and the initiation of anti-tumor activity attributable to CpG-ODNs present 
in bacterial DNA (Krieg, 1996,1999,2002). In these investigations CpG-ODN were 
characterized as specific sequences of oligodeoxynucleotides (ODNs) with unmethylated 
cytosine-phosphate-guanosine (CpG) dinucleotides. CpG-ODNs are 6-8 base nucleotide 
motifs consisting of CpG dinucleotides linked together by phosphodiester bonds and 
usually flanked by two 5’ purines and two 3’ pyrimidines. ODN uptake into the cells 
requires the participation of a voltage-gated channel due to the fact that they are 
polyanions and cannot diffuse across cell membranes freely (Krieg, 2002). These motifs 
are approximately 20 times more common in bacterial than in vertebrate DNA, due to 
CpG suppression and selective methylation (Cardon et al., 1994). These differences 
define CpG-ODNs as PAMPs and thus enable vertebrates to protect themselves against 
invading pathogens (Klinman et al., 1996). CpG DNA is recognized by a member of the 
Toll-like receptor (TLR) family of PRRs which triggers the host’s innate immune 
system. CpG-ODNs present in bacterial DNA represent one of the most recent examples 
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of PAMPs that influence adaptive immune responses by activating the innate immune 
system (Hemmi et al., 2000). 
The chemical structure of CpG-ODN greatly influences its ability to stimulate 
innate system cells and changes in the bases flanking the CpG dinucleotides have a great 
influence on the response because they influence recognition by the innate immune 
system. Although CpG-ODN uptake involves the binding to cell surface proteins with a 
non-specific antigen-receptor, the immunostimulatory effects of CpG-ODN are initiated 
by binding to an intracellular receptor, TLR9 (Krieg, 2002). Although this is not well 
understood, it is possible that TLR-9 may require a specific sequence in order to 
recognize CpG-ODN as a PAMP and bind to it as an antigen dependent response 
according to the sequences that are surrounding the CpG dinucleotides (Dalpke et al., 
2002; Pisetsky, 1999; Zhao et al., 1999). Some research groups have proposed different 
consensus base sequences for immunostimulatory DNA sequences in different species. 
The sequence GACGTT has been shown to be the optimal immunostimulatory sequence 
in mice and rabbits. This sequence is inhibitory for other species however, and distinct 
from the most stimulatory sequence for humans GTCGTT (Rankin et al., 2001). The 
immunostimulatory effects of CpG-ODNs have also been examined in both laboratory 
and domestic animals, including rabbits, sheep, horses, pigs, chickens, dogs, and cats. 
These investigations have demonstrated that responsiveness to unmethylated bacterial 
DNA sequences is a phenomenon conserved across many species (Rankin et al., 2001) 
They found that the main characteristic of ODN stimulating an immune response was the 
presence of a GTCGTT motif. They reported that three GTCGTT motifs within the 
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ODNs had a stronger and more consistent stimulatory effect, while ODNs with only one 
or two motifs did not activate the immune cells as consistently (He et al., 2003; Rankin 
et al., 2001; Vleugels et al., 2002). Most of the immune enhancing potential in different 
species is strictly CpG dependent and inversions to GpC abolish this activation (Ahmad-
Nejad et al., 2002). 
Modifications made in the natural backbone chemistry of the CpG may also 
affect the immunostimulatory effects of the bacterial DNA. Natural ODNs are linked by 
phosphodiester bonds which make them unstable and susceptible to endogenous 
nucleases which hydrolyze the phosphodiester bonds. To improve stability necessary for 
both investigation and practical use, synthetic CpG-ODNs have been designed. These 
analogs differ from the native forms by the substitution of a molecule of oxygen (O-) at 
the phosphate group in the nucleotide, thus making them more resistant to nucleases. 
Reported analogs include methylphosphonate ODNs, phosphoramidate ODN, 
phosphorothioate ODN, and (N3’---- P5’) phosphoramidate (Gallo et al., 2003). The 
most common ODN recently reviewed in the literature contained the phosphorothioate 
backbone due to their ability to increased nonspecific binding to different proteins, 
increased efficiency of binding to cell membranes, and a higher degree of cellular 
uptake. ODN with this backbone are taken up much more efficiently than ODN with the 
phosphodiester backbone and are more efficiently endocytosed than ODN with a 
methylphosphonate, in addition to having an in vivo half life of 48 hours as compared to 
the 5 minutes of the  phosphodiester backbone (Gallo et al., 2003; Pisetsky, 1999). The 
ability to induce proliferation of B cells, activate macrophages, NK cells or other 
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immune cells, will be either enhanced or decreased according to the susceptibility to 
degradation of the backbone (Krieg, 2002; Pisetsky, 1999; Zhao et al., 2000). 
The proposed processes of CpG-ODN stimulation is as follows. CpGs cross the 
cell membrane via sequence-non-specific receptor-mediated, clatherin dependent 
endocytosis. Endosomal maturation occurs and the ODN is recognized by TLR-9. 
Recognition through TLR-9 will induce an immune response involving both innate and 
adaptive immune system cells (He and Kogut, 2003; Krieg, 1999). The cellular 
activation by TLR-9 binding proceeds through a signaling cascade involving myeloid 
differentiation marker 88 (MyD88), IL-1R-associated kinase (IRAK), tumor necrosis 
factor receptor associated factor 6 (TRAF 6), nuclear factor kappa B (NF- κΒ) 
translocation, and up-regulation of genes involved in host defense. After this initial 
response, the triggering of TLR by specific CpG-ODN, results in TLR-9 specific 
immune responses (Ashkar and Rosenthal, 2002; Dalpke and Heeg, 2004; Krieg, 1999). 
CpG-ODN can also act directly on B cells triggering cytokine production (IL-6, and IL-
10), and immunoglobulin secretion. They’ve also been shown to activate dendritic cells 
to produce pro-inflammatory cytokines like IL-12 and stimulate antigen-specific T-cells, 
and proliferation of B cells (Krieg, 2002; Medzhitov, 2001).  
Chicken Coccidiosis 
 The etiological agents of chicken coccidiosis are a number of Eimeria species 
including, but not limited to, E. acervulina, E. tenella and E. maxima. Each species has 
characteristic prevalence, site of infection, and pathogenicity. All species, however, 
parasitize the epithelial cells of the intestinal lining and cause pathological changes 
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ranging from local destruction of the mucosa to systemic effects such as blood loss, 
shock, and death (Vermeulen et al., 2001). These changes lead to economic losses 
resulting primarily from decreased performance, such as feed conversion and weight 
gain. In a recent review (Allen and Fetterer, 2002), coccidial infections in poultry were 
calculated to cost the U.S. poultry producing industry in excess of $450 million 
annually. When worldwide production was taken into account this increased to over 
$800 million per year. While these costs take into account the cost of prophylactic 
medication and losses due to morbidity, mortality and poor feed conversion, it was 
further estimated that less than 20% of these losses were due to prophylaxis, with the 
other 80% due to decreased weight gain and poor feed conversion (Vermeulen et al., 
2001). Coccidial infections may be classified in one of three ways: (1) as clinical 
coccidiosis, characterized by mortality, morbidity, diarrhea, or bloody feces, as well as 
by adverse effects on economical performance; (2) as subclinical coccidiosis, by 
definition not immediately obvious, but causing reductions in weight gain and feed 
conversion efficiency of the host, without frank signs of disease; or (3) as coccidiasis, a 
mild infection causing no adverse effects on the host (Williams, 2002). 
Avian Eimeria spp. are a member of the phylum Apicomplexa. This phylum 
contains over 4600 species, many of which have medical and veterinary importance, 
including the etiological agents of malaria, babesiosis, and cryptosporidiosis. All species 
of this phylum are protozoan parasites which share an obligate parasitic life cycle and a 
unique complex of organelles involved in movement and invasion of host cells called the 
apical complex (Smith et al., 2002). The apical complex generally consists of three 
 25
organelles: micronemes, rhoptries, and dense granules (Tomley et al., 2001). The 
causative agents of chicken coccidiosis belong to the genus Eimeria, of the family 
Eimeriidae, of the order Eimeriida, of the class Coccidia. There are generally accepted 
to be seven species responsible for chicken coccidiosis: Eimeria acervulina, E. brunette, 
E. maxima, E. mitis, E. necatrix, E. praecox, and E. tenella. These species are 
differentiated based upon their site of development, morphological appearance, prepatent 
and patent times, immunological specificity and reproductive isolation. The species E. 
acervulina, E. maxima, and E. tenella are considered to be the most important to the 
poultry industry due to their ubiquity and pathogenicity (Schnitzler and Shirley, 1999).  
All Eimeria species have homoxenous life cycles, which have been well 
described by Fernando (Fernando, 1990). In general, environmentally resistant oocysts 
shed in feces undergo sporogony in the external environment. Sporogeny is a meiotic 
process requiring oxygen and taking about 24 hours in which a one-celled zygote within 
the oocyst wall undergoes a series of divisions to form sporozoites. Sporozoites are 
contained within sporocysts, with two sporozoites per sporocyst and four sporocysts per 
oocyst (Allen and Fetterer, 2002; Jeurissen et al., 1996). When ingested by a suitable 
host the oocyst undergoes excystation, the process of releasing infective sporozoites. 
During this process the oocyst wall is broken by the grinding action in the gizzard, 
releasing the sporocysts, and, through the actions of trypsin, bile, and CO2, the 
sporozoites are released.  Upon release the sporozoites actively penetrate the intestinal 
epithelial cells through the action of materials released from the apical complex. This 
entry is initiated by contact between the apex of the parasite and the host cell surface. 
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Progressive internalization follows proceeding from the anterior of the parasite to the 
posterior eventually enclosing the parasite within a vacuole within the host cell 
(Dubremetz et al., 1998). While the details of these actions are not known, invasion is 
dependent upon gliding motility of the parasite, which is dependent upon release of 
proteins from the microneme (Tomley et al., 2001). Rhoptry proteins may also be 
involved in invasion as they are found in the vacuole membrane early on, and dense 
granule proteins are found in the vacuole shortly after it closes (Dubremetz et al., 1998). 
Sporozoites of some species (E. brunette and E. praecox) develop within cells at the site 
of penetration, the villus tips, while sporozoites of other species (E. acervulina, E. 
maxima, E. necatrix, and E. tenella) are transported to the crypt epithelium, where they 
undergo development (Allen and Fetterer, 2002).  Within the host cells, sporozoites 
become rounded and transform into trophozoites which then enter an asexual 
proliferation phase. This involves schizogony, or merogony, in which nuclear division is 
followed by cytoplasmic differentiation, resulting in merozoites that are released into the 
intestinal lumen and reinfect other epithelial cells close to where they were released. 
After two to five merogonic generations, the sexual reproduction phase or gametogeny, 
occurs.  Merozoites enter host cells and develop into either male microgametocytes or 
female macrogametocytes.  A macrogametocyte is fertilized by a microgametocyte to 
form a zygote, which is then enveloped in an environmentally resistant oocyst wall. The 
oocysts are then released from the host cell and shed in the feces. Prepatent periods 
generally range from 4 to 5 days postinfection and maximum oocyst output ranges from 
6 to 9 days postinfection (Allen and Fetterer, 2002; Jeurissen et al., 1996). 
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Pathological changes in the intestine have been well characterized by a number 
of investigators. These are comprised of morphological and physiological changes, both 
of which contribute to an inability to normally absorb nutrients. As different species 
parasitize defined regions of the intestine these changes will be considered according to 
the region of the intestine affected. 
Eimeria acervulina is the primary species that affects the upper part of the small 
intestine.  There have been several reports indicating the changes in gut physiology 
during an E. acervulina infection and periods of malabsorption seen in chickens are 
generally attributed to epithelial destruction (Allen, 1987). Normal morphology of the 
duodenal villi ranges from fingerlike to spatulate-shape. E. acervulina infection was 
found to result in acutely truncated villi with no distinct tip as in uninfected intestines 
(Witlock and Ruff, 1977). Reduction of the mucosal layer in infected tissue has also 
been observed. This reduction became progressively more evident from 4-6 day post 
infection as fewer and fewer cells could be scraped off without disturbing the 
submucosal layers. However, by day 14 the intestine had recovered and appeared normal 
compared to uninfected birds (Allen and Danforth, 1984).  E. acervulina infection also 
decreased total alkaline phosphatase and sucrase activity in the upper and middle 
segments compared to controls at day 3, 5, and 7 postinfection while sucrase activity 
was significantly increased in the lower segment on day 7 postinfection (Allen, 1987). 
E. acervulina infections were also observed to affect zinc, oleic acid, and calcium 
absorptions while effects on protein and amino acid absorption were minimal (Turk and 
Stephens, 1967). An initial increase in absorption of zinc and oleic acid was observed at 
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the beginning of the infection but as the infection reached its acute phase zinc and oleic 
acid absorption levels were reduced by 25-40% as compared to uninfected birds. The 
maximal reduction occurred at the time of the most severe intestinal damage, however 
by the time visible intestinal damage was repaired the absorption rates for zinc were 
approximately double that of uninfected birds and those for oleic acid about 25% above 
uninfected birds (Turk, 1974) E. acervulina infection also slows the rate at which 
nutrients enter the bloodstream through the lumen of the intestine (Turk and Stephens, 
1967).  Infection increased the time to maximal levels of oleic acid in the bloodstream 
from 1-2 hours in non infected birds to approximately 8 hr in challenged birds. A 
decrease in gut motility may be responsible for this delay in absorption as well as the 
initial increase observed for zinc and oleic acid as it was hypothesized that a slow 
digestive tract rate would permit the nutrients to be in contact with the intestinal mucosa 
for a longer period of time.  (Aylott et al., 1968; Turk, 1974). Reduced rates of glucose 
and octanoic acid oxidation were also observed in birds infected with E. acervulina and 
were linked to the observation that mitochondria isolated from infected birds oxidized 
both octanoic and α-ketoglutaric acids at a lower rate than mitochondria from control 
chickens (Allen and Danforth, 1984). A shift in metabolism away from mitochrondrial 
oxidation towards the oxidation of glucose through the pentose phosphate pathway due 
to E. acervulina infection was also observed in the duodenum. This was indicated by a 
four-fold increase in the ratio at day 4 postinfection of metabolism of glucose through 
the glycolytic pathway versus the tricarboxylic pathway.  These findings indicate a shift 
 29
in metabolism away from mitochondrial oxidation towards oxidation of glucose through 
the pentose phosphate pathway (Allen and Danforth, 1984; Bloom and Stetton, 1953). 
Eimeria maxima is the primary species that infects the midgut on either side of 
Meckel’s diverticulum. Gross signs include a salmon exudate, thickened intestinal walls, 
petechial lesions, and hemorraging. Infection can be observed into the duodenum and as 
low as the intercecal junction (Schnitzler and Shirley, 1999). Normal villi in this region 
are shorter, broader, and generally apically squared off versus villi of the duodenum.  
Damage caused by E. maxima in the jejunum can include shortened villi, isolated 
patches of exposed connective tissue of the lamina propria, and epithelial sloughing, as 
oocysts formation occurs underneath the epithelium (Witlock and Ruff, 1977).  E. 
maxima infections can cause decreased absorption of nutrients as well as the above 
physiological changes in the jejunum.  Patterns of zinc and protein digestion and 
absorption patterns were similar to patterns observed in the duodenum throughout the 
infection, with increased zinc absorption during the first three days postinfection and 
returning to normal after recovery. Protein absorption remained equal to uninfected birds 
for the first three days and dropped to 58% of controls, but returned to levels 
significantly higher than uninfected birds upon recovery resulting in compensatory gain. 
Oleic acid and calcium absorption was reduced to 65% of the controls (Turk, 1974).  
Eimeria tenella is the primary species that infects the ceca. Uninfected villi of the 
large intestine are blunter, wider, and thicker as compared to those of the ileum (Witlock 
and Ruff, 1977). (Whitlock and Ruff, 1977).  The proliferation of E. tenella destroys the 
intestinal epithelium, causing the intestinal wall to become swollen, leading to bloody 
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diarrhea and fibrin clots in the feces (Jeurissen et al., 1996). Only minute changes were 
seen in absorption rates of calcium, oleic acid, zinc, and amino acids due to infection, 
thus leading to the conclusion that E. tenella infections have little effect on most nutrient 
absorption (Turk, 1974).  Although another investigator observed that infection with E. 
tenella significantly reduces plasma carotenoids, lipids, and proteins as well as body 
weight gain and feed efficiency, this may be due to a mechanism other than nutrient 
absorption such as anorexia or bleeding through the gross lesions associated with E. 
tenella infections (Conway et al., 1993). 
In addition to pathological changes and subsequent malabsorption of nutrients in 
the intestine, reduced weight gain and feed conversion due to anorexia is also involved. 
This has been attributed to a number of mediators including IL-1 and leptin (Klasing et 
al., 1987; Min et al., 2004). Other nonspecific host responses, not necessarily linked to 
decreased performance, have also been observed in experimental infections. Modulation 
of oxidative stress by generation of free radicals such as superoxide and nitric oxide 
(NO) has been reported to be an important regulator of both host immunity and host-
parasite interactions and has been reported to occur in Eimeria infections (Allen, 
1997a,b). Alterations in whole body thiol balance, specifically reduced blood levels of 
glutathione during infections, and production of acute phase proteins such as alpha-1-
acid glycoprotein, hemopexin, and ovotransferrin, as well as metal binding proteins, 
have also been observed in infections with Eimeria, although the role these substances 
have in infection and immunity are not currently known (Min et al., 2004).  
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The most extensively studied responses to infection with Eimeria have been 
those of the immune response. There are three key points in the life cycle of Eimeria 
where the host immune system can inhibit the parasite. These are the interaction of 
parasites with host intestinal epithelium cells, within the epithelium in proximity to 
IELs, and during passage through the lamina propria to the crypt epithelium (Jeurissen et 
al., 1996). Likewise, the GALT of the chicken serves three functions in defense against 
enteric pathogens. These are processing and presentation of antigens, production of 
intestinal antibodies, and activation of cell mediated immunity (CMI) (Min et al., 2004). 
Both recent and past investigations have elucidated the relative importance of both 
humoral and cell mediated immunity on Eimeria infection.  
It is well established that infection with the three major Eimeria species results in 
parasite specific serum IgG(Y), IgA and IgM levels that are generally detectable within a 
week of infection and reach maximum levels at about two weeks (Galmes et al., 1991; 
Rose, 1971). Intestinal antibodies have also been detected both at the site of infections 
and distal areas, with levels of IgM and IgA at the site of parasite replication being 
greater than those at distal sites but those of IgG not differing. The pattern of antibody 
production was observed to be the same in the intestine as in the serum with the 
exception of a transitory rise in IgA in the serum in E. acervulina infections and a lack 
of intestinal IgA in the first week in E. tenella infections (Girard et al., 1997). The role 
of antibodies in Eimeria infections is likely not direct. There is evidence that serum 
transfer from E. maxima infected birds can reduce oocyst production in chicks infected 
with E. maxima (Rose, 1971). Immunization of hens with gametocyte antigens from E 
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maxima was also observed to decrease oocyst production chicks infected with E. 
maxima, E. acervulina and E. tenella (Wallach et al., 1995). A monoclonal antibody to 
an E. acervulina conoid antigen was also described that inhibited invasion of multiple 
species of Eimeria in vitro (Sasai et al., 1998; Sasai et al., 1996). In contrast there have 
been studies that found that immunity to infection was not reduced in bursectomized 
chickens and that antibody levels did not correlate to oocyst output (Lillehoj, 1987; 
Talebi and Mulcahy, 1995). Therefore, considering the above information, it is thought 
that the role of parasite-specific antibodies is that of reducing the effective dose through 
parasite agglutination, neutralization, steric hinderance, and reduced motility as opposed 
to direct antibody mediated killing (Lillehoj and Lillehoj, 2000). 
There is considerable evidence for the importance of CMI in the protection from 
Eimeria as mediated by antigen specific and non-specific activation of T-cells, natural 
killer (NK) cells, and macrophages. T-cells in particular are important in protection from 
Eimeria infections both from species specific for the chicken and foreign-host species 
(Lillehoj et al., 2000). A number of studies investigated the effects of cyclosporine-A 
(Cs-A), betamethasone, and dexamethasone on infection with Eimeria tenella. Cs-A 
enhanced resistance to primary infection when given with the innoculum, but when 
given before or prior to secondary infection decreased or eliminated protective immunity 
(Lillehoj, 1987). Additionally this same suppressive effect was observed when Cs-A was 
given before inoculation with turkey specific Eimeria (Kogut and Eirmann, 1991). 
Administration of both betamethasone and dexamethasone enhanced the severity of 
Eimeria infections and dexamethasone was observed to decrease T-cell proliferation 
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with no changes in antibody production and allow the development of turkey coccidia in 
chickens (Isobe and Lillehoj, 1993; Long and Rose, 1970; McLoughlin, 1969). Other 
studies investigated the relative contribution of CD4+ and CD8+ cells using monoclonal 
antibody-activated depletion. CD8+ depleted animals produced significantly fewer 
oocysts after a primary infection but significantly more after a secondary infection with 
either E. acervulina or E. tenella. In addition CD4+ depleted chickens produced 
significantly more oocysts after a primary infection with E. tenella, but not E. acervulina 
(Trout and Lillehoj, 1996). While CD4+ cells represent a minor population of the 
chicken IEL, increases were observed in the duodenum 4 to 8 days after infection with 
E. acervulina and in the ceca 8 days after infections with E. tenella (Bessay et al., 1996). 
It is thought that the role of CD4+ T cells in coccidiosis may involve the production of 
soluble cytokines such as IFN-γ (Yun et al., 2000b). 
Another line of investigation involved the use of two inbred strains of chickens 
displaying different levels of susceptibility to coccidiosis with the SC strain being more 
resistant than the TK strain. These strains were shown differ in their T-cell sub-
populations, particularly the γδ TCR+CD8+ cell in the intestine after infection with 
Eimeria acervulina (Lillehoj, 1994). Specifically in Eimeria acervulina infections, an 
increased percentage of γδ T cells were observed in the duodenum after post primary and 
secondary infections (Choi and Lillehoj, 2000). When the SC and TK lines were 
compared, this increase was observed to occur four days earlier in the SC line as 
compared to the TK line. An increase in αβ T cells was also observed in both lines by 
six days after the secondary infection (Choi et al., 1999).The importance of CD8+ T 
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cells was also evidenced by the significant increases in CD 8+ T ells after E. acervulina 
infection four days post infection, with a higher increase for the SC line as compared to 
the TK line (Lillehoj et al., 2004). 
Macrophages have also been implicated in immunity to coccidiosis. Significant 
numbers of sporozoites have been found within macrophages after primary and 
secondary infection with Eimeria acervulina (Trout and Lillehoj, 1995). This 
observation and the fact that macrophages produce a significant amount of IFN-γ 
following stimulation with both sporozoites and merozoites, lead investigators to believe 
that macrophage involvement in immunity is through modulation of host response 
(Zhang et al., 1995). Additionally, NK cell activity was increased in chickens after both 
a primary and secondary infection with Eimeria. NK cell activity in two inbred strains 
was positively correlated with resistance (Chai and Lillehoj, 1988; Lillehoj, 1989).  
As cytokines play a major role in the regulation of immune responses, their role 
in Eimeria infections has also been investigated. However, due to the fact that 
identification of many chicken cytokines is recent, only a few have been investigated in 
this capacity. Interferon-γ is the most extensively characterized cytokine in regards to 
Eimeria infection. It has been examined through both quantitative RT-PCR and gene 
expression profiling (Choi et al., 1999; Laurent et al., 2001; Min et al., 2003; Yun et al., 
2000a). IFN-γ mRNA was detected in the cecal tonsils and spleen, but not the 
duodenum, of SC strain chickens challenged with E. acervulina and was increased over 
200-fold in the cecum and jejunum of specific pathogen free (SPF) chickens challenged 
with either E. acervulina or E. maxima(Choi et al., 1999; Laurent et al., 2001). After 
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both primary and secondary E. tenella infection, a marked increase in IFN-γ was 
reported in the spleen, cecal tonsils am IELs (Lillehoj et al., 2004).The role of IFN-γ was 
directly assayed by injecting recombinant cytokine into E. acervulina infected SC and 
TK chickens, resulting in significant decreases in both body weight loss and oocyst 
shedding. It was also observed that E. tenella sporozoites were inhibited from 
undergoing development in a cell line stably transfected with chicken IFN-γ (Lillehoj 
and Choi, 1998). These results demonstrate the inhibitory effect of IFN-γ against 
Eimeria, but the precise mechanisms have yet to be elucidated. 
Interleukin-2 (IL-2) is a potent growth factor involved in T and B cell 
differentiation and NK cell activation. Increases in IL-2 mRNA expression in the spleen 
and intestine were observed after both primary and secondary infection with Eimeria 
acervulina (Choi and Lillehoj, 2000). Tumor necrosis factor alpha (TNF-α) is a potent 
inflammatory cytokine with pleiotropic functions including NO release and induction of 
MHC class II on macrophages (Staeheli et al., 2001). A TNF-like factor has been 
experimentally produced following infections with both E. maxima and E. tenella in a 
biphasic fashion. The first peak was associated with pathogenesis and the second with 
induction of immunity (Byrnes et al., 1993). Additionally treatment of chickens with 
antibodies raised against TNF resulted in partial reduction of weight loss induced by E. 
tenella infection (Zhang et al., 1995). Transforming growth factor beta (TGF-β) is a 
pleiotropic anti-inflammatory cytokine that stimulates repair of damaged mucosal 
epithelium and four isoforms have been identified in the chicken (Staeheli et al., 2001). 
After E. acervulina infection TGF-β4 expression increased 5 to 8 fold in the intestinal 
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IEL and 2.5 fold in the spleen, whereas TGF-β2 and TGF-β3 remained the same 
(Jakowlew et al., 1997). Interleukin-6 is a pleiotropic lymphokine originally described as 
a T-cell derived lymphokine and induces the final maturation of B cell into antibody 
producing cells (Staeheli et al., 2001). An IL-6 like factor was detected in serum from E. 
tenella infected chickens during the first few hours indicating a possible role in the 
development of acquired immunity (Lynagh et al., 2000). Interleukin-1 (IL-1) is 
involved in T cell commitment, induction of fever, activation of the hypothalamic-
pituitary axis and glucocorticoid secretion, triggering of the acute-phase response, and 
activation of the vascular endothelium (Staeheli et al., 2001). E. tenella and E. maxima 
infections induce a 27-80 fold increase in production of IL-1β mRNA in the jejunum or 
cecum at seven days post infection (Laurent et al., 2001). IL-10 is primarily involved in 
modifying immune responses through direct effects on T cells, B cells, APCs and NK 
cells by promoting the development of Th2 responses. In E. maxima infections a 
significant increase in IL-10 mRNA was observed in both the small intestine and spleen 
of a susceptible line of chickens (line 15I) as compared to a resistant line (line C.B12). 
However, the fact that levels of IFN-γ mRNA expression were the same between the two 
lines, indicates that the susceptibility may be due to a higher constitutive expression of 
IL-10 (Laurent et al., 2001). 
Methods of Control of Coccidiosis 
 Considering the importance of poultry production and the adverse effects of 
coccidiosis on commercially raised poultry, control of this disease is very important. 
Biosecurity plays a large part but, due to the ubiquity of coccidial species, is not an 
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adequate control. Management strategies differ between the United States and Europe. 
Operations in Europe and Canada do a thorough clean out between flocks, while U.S. 
operations generally remove caked litter, let the house air out, and then top dress with 
fresh litter. As the use of live vaccines and the incidence of drug resistance increases in 
the U.S., it is thought that we may see changes in these practices (Allen and Fetterer, 
2002).  
Since the introduction of the first true anticoccidial drugs in the 1940s, new 
anticoccidals have been introduced in increasing numbers, and the judicious use of these 
drugs has allowed the increased availability of high quality affordable poultry products 
to the consumer (Allen and Fetterer, 2002; Stephen et al., 1997). Despite the fact that in 
the 1960s it was stated that resistance did not represent any serious problem in the 
control of coccidiosis, this clearly is no longer the case, as resistance to every 
anticoccidial available has been observed (Chapman, 1993). Anticoccidial drugs can be 
roughly divided into two categories. The first include chemicals which have specific 
modes of action against parasite metabolism, such as amprolium, clopidol decoquinate, 
and halofuginone. The second category act through general mechanisms of altering ion 
transport and disrupting osmotoic balance and are the polyether ionophores such as 
monensin, lasalocid, salinomycin, narasin, and maduramycin. Despite the success of 
these compounds, some resistance has developed to all these chemotherapeutic agents 
(Allen and Fetterer, 2002). This is probably due to the fact that most drugs target the 
asexual stages, the first or second generation meronts. Since the asexual stages are 
haploid, the complexities of selection present in diploid organisms are absent. This 
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means that resistant mutants will be immediately selected for and quickly dominate over 
non-resistant forms (Chapman, 1993). This fact, along with consumer concern about 
drug residues in food, has promoted the development of alternative forms of control such 
as live oocyst vaccination (McEvoy, 2001).  
 The only current alternative to the use of anti-coccidial drugs is live oocyst 
vaccination (Chapman et al., 2002). The basis for the use of live oocyst vaccines is the 
fact that, after an infection, the host is immune to subsequent infections by the same 
species (Yun et al., 2000b). This immunity is species specific, therefore vaccines are 
formulated with multiple species. In addition, the use of low numbers of parasite 
administered multiple times, or trickle immunization, also results in species specific 
protective immunity (Vermeulen et al., 2001). Live vaccines have been used by the 
poultry industry for over 50 years, primarily for broiler breeders and replacement layer 
stock (Chapman et al., 2002). The reluctance in using live vaccines in broilers stems 
from decreased weight gain and feed conversion due to vaccination as compared to 
medicated birds, as well as the possibility of introducing new species into the rearing 
house. Both the development of attenuated vaccines and improved application methods 
have alleviated some of  the concern and led to an increased in use in broilers (Allen and 
Fetterer, 2002; Chapman et al., 2002). 
 There are currently a number of commercially available live vaccines for 
coccidiosis that fall into two classifications, live virulent and live attenuated (Vermeulen 
et al., 2001). Virulent vaccines are wild type field strains that have been isolated from 
commercial poultry operations, presumably before the emergence of drug resistance. 
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Attenuated vaccines are obtained either by selection for early maturation (pre-
cociousness) or through serial passage through embryonated eggs (TA lines). The four 
dominant commercial vaccines used by the poultry industry go by the trade names 
“Coccivac”, “Immucox”, “Livacox”, and “Paracox”. Of these the “Coccivac” and 
“Immucox” are live virulent vaccines, “Paracox” is precocious, and LivaCox is 
precocious or TA line. They all incorporate between two and eight species of Eimeria 
dependent upon the market they are targeted to and all provide solid immunity to 
coccidial infection when applied carefully and under good management conditions 
(Danforth, 1998; Vermeulen et al., 2001). 
 As mentioned above efficient delivery of vaccine is crucial to development of 
protective immunity. Delivery in the drinking water has for the most part been replaced 
by spraying the vaccine on the feed or the use of an edible colored gel containing the 
oocysts. While these are generally considered to result in uniform exposure, widespread 
use of spray cabinets for viral vaccination has prompted the use of this method. This 
procedure is automated and through the use of red dye in the vaccine it has been 
observed that between 90 and 95% of the chicks receive the vaccine. It is then further 
spread through preening behavior (Chapman et al., 2002). Despite the ease of use with 
spray cabinets, a series of field trials compared spray cabinet, gavage, slurry and gel 
delivery and concluded that gel delivery gave the best protection to E. maxima infection 
(Danforth, 1998). Another attractive method of vaccination is in ovo delivery, direct 
injection of a vaccine into an 18 day old embryo. This is attractive due to the fact that it 
is already widely used for vaccination to viral diseases and therefore is already in place. 
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Recent studies have demonstrated that injection of infective stages of Eimeria both cause 
an infection in the chick and can contribute to immunity (Weber and Evans, 2003; 
Weber et al., 2004). 
 As stated above in some cases live oocyst vaccination has been observed to lead 
to decreased weight gain. One possible solution to this is the use of adjuvants to improve 
immunity to the vaccine and possibly provide some protection to the chick during 
vaccination. The recently described adjuvant CpG-ODNs, with its immunostimulatory 
properties, would seem to be an excellent candidate for this application. A recent study 
using SC and TK lines of chickens examined the effects of different delivery methods of 
CpG-ODNs twenty-four hours before an infection with E. acervulina on weight gain, 
oocyst production, and production of antibodies to the antigen 3-1E. Weight gain was 
increased when CpG-ODNs were given intravenously (I.V.) to day old TK chicks, but 
not orally to either. I.V. injection also resulted in an increase in weight gain dependent 
upon the backbone used and the dose given. Oocyst shedding was decreased in only the 
TK line of chickens and no differences in antibody responses were observed (Dalloul et 
al., 2004). These results suggest that immunostimulatory adjuvants may be useful in 
reducing reduction in body weight gain due to live parasite vaccination. 
SUMMARY AND CONCLUSIONS 
 A major research interest in our laboratory at present is the investigation of 
immune responses to enteric pathogens in poultry, the response to vaccination, and the 
subsequent improvement of vaccination strategies. This is being done through 
investigation of alternate modes of vaccine delivery and immunomodulation of the host 
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immune response through the use of the recently described mucosal adjuvant CpG-
ODNs. In the present investigations, we evaluated a means for delivering protein antigen 
in the drinking water and the use of CpG-ODNs in order to improve this response. We 
then investigated three methods of modulating the host’s immune response with CpG-
ODNS when vaccinated with a field strain of E. acervulina or challenged with field 




IMMUNOGENICITY OF AD LIBITUM DRINKING WATER 
ADMINISTRATION OF BSA IN LEGHORN CHICKENS* 
 
INTRODUCTION 
Oral administration of solubilized non-replicating protein antigen has been 
reported to lead to oral tolerance in many mammals resulting in transitory induction of 
secretory IgA (sIgA) and suppression of systemic IgG, whereas other mammals, such as 
the guinea pig, are anaphylactically sensitized by administration of oral antigen 
(Challacombe and Tomasi, 1980; Miller and Cook, 1994). In chickens, however, protein 
antigen administered orally to chicks older than ten days of age induces a strong humoral 
immune response involving elevated serum titers of both IgG and IgA isotypes and does 
not sensitize them to delayed type hypersensitivity after repeated antigen exposure 
(Klipper et al., 2001; Miller and Cook, 1994). Since resistance to some pathogens 
correlates with sIgA secretion at mucosal sites, rather than systemic IgG or IgM 
circulating antibody levels, this difference may have important implications for subunit 
vaccine delivery in commercial poultry production (Davis et al., 1978; Tomasi and 
Bienenstock, 1968). 
Previous studies have determined a number of factors that influence the response 
to orally administered protein antigen in chickens. These factors include the form in 
                                                 
* Reprinted with permission from “Immunogenicity of ad libitum drinking water administration of BSA in 
Leghorn chickens” by Ameiss, K.A., H. D. Danforth, A.P. McElroy, A. Barri, L. Berghman, and D.J. 




which it is given, the time at which it is administered, the route, and concentration of 
antigen administered. When BSA was administered in a powdered form to chicks older 
than 10 days of age, it neither induced a systemic immune response nor increased the 
response to subsequent immunizations. This is in direct contrast to the responses 
observed in similar animals to dissolved BSA fed orally, which included a systemic 
antibody response. However, chicks younger than 8 to10 days of age are not responsive 
to orally administered dissolved BSA and develop tolerance to it dependent upon the 
initial dose (Klipper et al., 2001). This responsiveness to antigen correlates with the 
colonization of the gut mucosa with both B and T lymphocytes and subsequent cytokine 
expression and production necessary for regulating humoral responses at mucosal sites 
(Bar-Shira et al., 2003). The route of administration has also been demonstrated to be a 
factor. Three administrations of BSA via oral gavage one week apart were shown to 
induce low and inconsistent IgG levels without adjuvant (Hoshi et al., 1999);(Hoshi et 
al., 1998), whereas when the same solution was fed in trickle fashion via syringe resulted 
in a strong and consistent IgG response. When dosage or concentration of this type of 
antigen administration was investigated for optimal responsiveness, it was determined 
that as little as 2 mg fed for six days consecutively was fully immunogenic (Klipper et 
al., 2000). 
Given the evidence of robust humoral responses elicited to orally administered 
solubilized BSA and the fact that tolerance seems to be an age dependent event in 
chickens, oral administration of protein antigen may be practical in a commercial setting 
for mass vaccination. In order for this approach to vaccination to be practical, mass 
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immunization strategies must be investigated. The most efficient method for oral 
administration would be via the drinking water. It was the purpose of this study to 
evaluate the efficacy of low dose, ad libitum administration of a protein antigen in the 
drinking water to immunologically mature chickens for eliciting systemic and local 
intestinal antibody responses. This route of administration was compared to both oral 
gavage and i.p. routes of administration.  
MATERIALS AND METHODS 
Experimental Animals 
Single-comb-white-Leghorn (SCWL) chicks were obtained from a local 
commercial hatchery (Hyline International, College Station, TX) on day of hatch and 
placed in floor pens at an initial density of 18 birds per m2 with pine shavings as litter. 
They were maintained at age appropriate temperature and fed a corn-soy chick starter 
ration, lacking animal fat or protein, and formulated at or above NRC recommendations 
(National Research Council, 1994) for poultry and water ad libitum. 
Experimental Design and Immunization 
 In Experiments 1 and 2, day of hatch chicks were divided into the following five 
experimental groups: negative control, i.p. alum control, i.p. BSA, BSA gavage, and 
BSA in drinking water. To immunize chickens to BSA by i.p. administration, two 
successive i.p. injections consisting of 5 µg precipitated BSA in 5 mg alum (AlK(SO4)2) 
were administered to chickens on days 12 and 18 of each experiment.  Non-immunized 
alum control chickens received i.p. injections of 5 mg alum only at the same time points 
of each experiment.  Chickens in gavage groups received a per os gavage once daily 
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with 12.5 mg of BSA in 0.5 ml water on days 12 through 17 of each experiment. 
Chickens in the drinking water group were given ad libitum access to a bell drinker with 
water containing 1.4 mg/ml BSA on days 12 through 17 of each experiment.  
Sampling 
 On day twenty-five of life, seven days following the final i.p. immunization and 
eight days following the last oral administration, 1 ml of blood was drawn from the wing 
(bicipital) vein and allowed to clot for serum collection. Serum was transferred to a clean 
microcentrifuge tube and then frozen at –20°C until assayed by indirect ELISA. The 
chickens were then euthanized, and, in Experiment 2 only, intestinal sections were 
collected to assay local intestinal antibody production stimulated by the evaluated routes 
of immunization. 
Ex vivo Culture of Intestinal Tissue 
To measure antigen-specific IgG or IgA production in intestinal sections 
following immunization in Experiment 2, we adopted the method described by 
Zigterman and co-workers (Zigterman et al., 1993) with slight modification. 
Immediately following euthanasia, intestinal tissue corresponding to the distal ileum, 
cecal tonsils, and the distal cecum were removed and immersed in ice cold Hank’s 
Balanced Salt Solution (HBSS) containing 500 IU/ml of penicillin and 500 µg/ml of 
streptomycin. Gut contents were removed by gently flushing each tissue section with 
HBSS. Tissues were then cut into pieces weighing 0.3 g each, and each tissue was then 
cut into three smaller pieces and again washed with HBSS containing penicillin and 
streptomycin. Tissues, respective for each animal sampled within each experimental 
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group, were then suspended in 6 ml of RPMI 1640 supplemented with 100 IU/ml 
penicillin, 100 µg/ml streptomycin, 100 µg/ml gentamicin, and 40 mM HEPES. 
Suspensions were centrifuged (5 min, 300g), and 800 µl aliquots of supernatant (ileum, 
cecal tonsil, or distal cecum supernatant; labeled t = 0) were taken. The tissues were 
resuspended and incubated at 41°C, 5% CO2, 95% air in twelve well culture plates for 
16 hours. After 16 h culture, aliquots were removed and labeled as t = 16 for each 
respective sample. BSA-specific IgG, IgM, and IgA titers measured during ex vivo 
intestinal culture for each experimental animal were determined using indirect ELISA by 
subtracting the t=0 values from t=16. 
Absorption of Cross-reactive Antibodies and ELISA 
Serum or collected medium from intestinal tissue culture, respective for each 
experimental animal evaluated, was pre-incubated overnight at 4°C with 40 mg of 
chicken albumin per ml and diluted to 1:320, 1:640 and 1:1280 for serum samples and 
1:5, 1:10 and 1:20 for intestinal media samples to eliminate the presence of any potential 
cross-reactive antibodies.  Indirect ELISA was performed on all serum or intestinal 
tissue culture samples using 96 well plates coated with 5 µg of BSA per well.  Following 
overnight incubation, plates were rinsed with PBS-T (pH 7.4, 0.5% Tween 20), 150 µl of 
serum or media was added, and plates were agitated for an additional 2 hours. Plates 
were again rinsed, goat anti-chicken IgG, IgM, or IgA (Bethyl Laboratories, 
Montgomery, TX) was added to each well, and plates were agitated for 1 hour. Plates 
were rinsed, and a substrate solution containing 100µl dimethyl sulfoxide (DMSO) with 
1 mg tetramethlybenzidine (TMB), and 10 µl of hydrogen peroxide (H2O2) in 10ml of 
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sodium acetate buffer (pH 5.5) was added. After 15 minutes the reaction was stopped by 
adding 50µl of 1 M sulfuric acid. Absorbance was read by a multi-well plate reader at a 
wavelength of 450 nm. 
Statistical Analysis  
 Samples were read in duplicate and normalized for plate effects by dividing by a 
positive standard. The mean absorbance of samples was log transformed to normalize 
variance and analyzed using the Univariate General Linear Model procedure for analysis 
of variance (SPSS 11.01, Chicago, IL). Statistically different means (P < .05) were 
further separated using Duncan’s Multiple Range Test (SPSS, v. 11.0) 
RESULTS AND DISCUSSION 
It has been well established that oral administration of protein in solution is 
immunogenic and not tolerogenic in domestic chickens. (Klipper et al., 2000; Miller and 
Cook, 1994). This has been demonstrated by feeding discrete amounts of solubilized 
antigen to chickens of an immunocompetent age for six to 14 consecutive days (Klipper 
et al., 2000; Miller and Cook, 1994). Following these regimes, specific antibody 
production has been reported in both the serum and the bile. Alternative approaches of 
antigen administration, such as once a week feedings, do not induce an humoral response 
in the absence of adjuvant (Hoshi et al., 1998; Hoshi et al., 1999).  
In the present study, serum IgG responses measured in Experiments 1 and 2 are 
shown in Tables 1 and 2. Although the background absorbance varied between 
experiments, trends and observed significance between experimental groups in both 
experiments were observed to be the same. BSA administered ad libitum in the drinking 
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water resulted in the generation of greater antibody titers (P < 0.001) when compared to 
titers in chickens in negative control and oral gavage experimental groups. Similarly, 
IgG titers in chickens in the i.p. BSA group were significantly greater (P < 0.001) than 
all other experimental groups excluding the drinking water BSA group, indicating oral 
drinking water antigen administration was as efficacious as i.p. administration with 
adjuvant.  
Billiary IgA responses, as shown in Tables 1 and 2, revealed a different trend. 
Although the background was high in both experiments, BSA administered to chickens 
in the drinking water induced higher (P < 0.001) levels of IgA than i.p., gavage, or either 
of the control groups. Intestinal IgG responses (Table 2) were similar to responses 
measured in the serum. In the distal ileum, cecal tonsils, and cecum, IgG levels were 
higher (P< 0.05) in chickens in the i.p. BSA and drinking water experimental groups 
than levels observed in both control groups as well as the oral gavage group. Intestinal 
IgA responses, however, did not differ significantly between the groups in any of the 
intestinal regions evaluated (data not shown). 
These data confirm that oral administration of solubilized BSA induces both 
serum and bile antibody responses and also establishes that a local intestinal antibody 
response is measurable seven days following the last time of immunization, indicating 
specific antibodies were produced by lymphocytes in the distal ileum, cecal tonsils, and 
distal cecum in response to oral BSA immunization. Although measured responses 
consisted of primarily IgG secretion, it bears mentioning that only one time point during 
this evaluation of intestinal antibody secretion was evaluated.  The fact that sIgA levels 
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were observed not to differ at seven days after the last immunization, where IgG 




TABLE 1:  BSA-specific serum IgG and bile IgA responses in chickens immunized 
with BSA by intraperitoneal or oral routes of administration in Experiment 1 
 




Distal Ceca Bile 




ND ND 0.68 ± 
0.16B 
BSA – Water 10 0.47 ± 
0.07A 
ND ND ND 1.35 ± 
0.10A 
BSA – Gavage 9 0.15 ± 
0.07B 
ND ND ND 0.41 ± 
0.11B 
i.p. – Vehicle 3 0.02 ± 
0.12B 
ND ND ND 0.74 ± 
0.18B 
i.p. - BSA 9 0.59 ± 
0.07A 
ND ND ND 0.89 ± 
0.11B 
 
Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  
Serum samples were diluted 1:640, bile sample were diluted 1:80, and media from 
intestinal culture were diluted 1:10.  Means ± S.E. within columns with no common 




to challenge with Eimeria species or a purified recombinant antigen from E. tenella 
(Girard et al., 1997; Girard et al., 1999).  It is indeed likely that if measured at a later 
day, IgA production may have been elevated in the intestinal sections tested, as seen in 




TABLE 2:  BSA-specific serum IgG, intestinal IgG, and bile IgA responses in chickens 





Serum Ileum Cecal Tonsils Distal Ceca Bile 




0.03  ± 0.01b 0.03 ± 0.01b 0.73 ± 0.14B 




0.12  ± 0.03a 0.12   ± 0.03a 1.11 ± 0.09A 
BSA – Gavage 5 0.20 ± 
0.07B 
0.03 ±  
0.01b 
0.05 ± 0.02b 0.05 ± 0.02b 0.42 ± 0.09 B 




0.01 ± 0.01b 0.01 ±  0.01b 0.43 ± 0.16 B 




0.12  ± 0.04a 0.12 ± 0.04a 0.69 ± 0.09 B 
 
Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  
Serum samples were diluted 1:640, bile sample were diluted 1:80, and media from 
intestinal culture were diluted 1:10.  Means ± S.E. within columns with no common 
superscript differ significantly at the following levels of significance:  aP<0.05 or 
AP<0.001.  ND: Not determined. 
 
 
As stated above, ad libitum, oral administration of solubilized protein antigen 
elicits an immune response in commercial lines of SCWL chickens. While this study 
was limited to SCWL chickens, other studies have reported a similar responsiveness to 
oral BSA administration in broiler chickens (Klipper et al., 2000). When compared to 
negative controls and crop-gavaged chickens, animals receiving BSA by drinking water 
administration produced higher levels of antigen specific antibodies. It is worthwhile to 
note that IgG levels in those chickens were not significantly different than levels in 
chickens given two i.p. injections of BSA with alum as an adjuvant.  
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Observations of drinking water administration being more efficacious in eliciting 
humoral immune responsiveness were also seen by Klipper and co-workers (Klipper et 
al., 2001). One possible explanation may involve crop distention associated with the 
single bolus per os administration.  Crop distention, in this scenario, may likely result in 
the release of proteolytic pepsinogen and HCl by the proventriculus, which might result 
in the degradation of the protein before adequate amounts could reach lymphoid tissue at 
distal sites in the intestine. The findings of Klipper et al. (2000), indicating that feeding 
powdered forms of BSA to mature chicks induced neither an immune response or 
tolerance, and Hoshi et al. (1998) by demonstrating that gavage administration did not 
induce immunity and may induce tolerance, adds support to this speculation. 
Regardless of the mechanisms involved in the observed responsiveness to oral 
antigen in the chicken, the present investigation clearly confirms that solubilized oral 
protein administration induces both systemic and local humoral immune responses. 
These findings suggest that subunit protein vaccines, administered by a drinking water 
route of delivery, may be a feasible option for commercial productions or smaller 
breeder flocks.  While additional investigation into such a route of mass vaccination is 
clearly needed to support such a claim, the ease of administration to large numbers of 
animals by this approach represents a distinct advantage, even more so than what exists 
for many live and attenuated vaccines for enteric pathogens, which are presently given 
orally. Additional research should also include investigation into variability in 
immunogenicity of antigens isolated from specific pathogens, as well as the level of 
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protection induced by these antigens. The duration of immunity elicited by oral protein 




EFFICACY OF ORAL CPG-ODNS AS MUCOSAL ADJUVANTS WHEN CO-




In all commercial poultry operations, the overwhelming majority of infectious 
pathogens access the host via the mucosal surfaces of the respiratory, genitourinary and 
gastrointestinal tracts (Staats et al., 1994).  While many live and attenuated vaccines 
used in production operations involve oral administration or delivery, their efficacy 
following administration by this route is often variable (Vermeulen et al., 2001). Since 
oral vaccination appears to be one of the most effective and feasible ways to induce 
mucosal immunity in commercial operations, it stands to reason that killed or subunit 
vaccines may also be administered by this route. However, killed and subunit vaccines 
are often not immunogenic or require multiple boosts to be effective (Husband, 1993; 
McGhee and Kiyono, 1993), therefore, an adjuvant that can be administered orally and is 
capable of improving overall immunogenicity is needed.  
Bacterial toxins such as cholera toxin (CT) and the structurally related 
Escherichia coli heat-labile enterotoxin (LT) are both potent mucosal adjuvants that 
have been successfully used in several animal models.  Orally administered CT induces 
a strong mucosal response in both mice and layer type chickens when given with non-
replicating antigen (Girard et al., 1999; Lycke and Holmgren, 1987).  Similar use of LT 
has been less successful in both mammals and birds (Lee et al., 1999; Rice et al., 1997).  
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Despite the reported efficacy of both adjuvants, both their potential for toxicity and 
present high cost make them impractical for commercial use. 
Immunostimulatory DNA sequences (ISS) represent a potential new class of 
mucosal adjuvants.  ISS are DNA sequences containing unmethylated CpG (cytosine-
phosphate-guanosine) dinucleotides in a specific base context, or motif.  They are most 
commonly given in the form of synthetic oligodeoxynucleotides (ODN) made with a 
nuclease resistant phosphorothioate backbone (McCluskie et al., 2000).  Several 
characteristics of CpG-ODNs contribute to its potential usefulness as a mucosal 
adjuvant. CpG-ODNs have been reported to stimulate B cells to proliferate, secrete 
immunoglobulins, and secrete IL-6 and IL-12, in addition to protecting them from 
undergoing apoptosis (Krieg, 2001). Additionally, CpG-ODNs have been shown to 
enhance expression of class II MHC and B7 costimulatory molecules on antigen 
presenting cells (APCs) which leads to enhanced antigen presentation to lymphocytes.   
Activation of monocytes, macrophages, and dendritic cells to secrete select cytokines 
and chemokines which increase T-helper functions has also been reported (Krieg, 2002). 
Stimulatory CpG motifs generally have an ApA, GpA or GpT dinucleotide on the 
5’ side with two pyrimidines, typically TpT, on the 3’ side (Yi et al., 1996). A large 
degree of conservation among species in term of actual motif recognition apparently 
exists.  While in vitro assays determined that GACGTT was optimal for stimulation of 
inbred laboratory murine and rabbit lymphocytes, most other species of veterinary 
importance, including chicken, responded optimally to the GTCGTT motif (Rankin et 
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al., 2001).  In addition to the base sequence, the inclusion of spacers between multiple 
copies of the motif also influenced responses (Rankin et al., 2001).  
The majority of work performed to date using CpG-ODN as adjuvants has 
involved parenteral immunization of mice, non-human primates and, in one case, sheep 
(Chace et al., 1997; Davis et al., 2000; Rankin et al., 2001).  More recently it has been 
demonstrated that immunization with CpG-ODNs intranasally, intrarectally, and orally is 
immunostimulatory in mice, with intranasal and oral being the most effective routes of 
administration (McCluskie and Davis, 2000). Investigations of the effectiveness of CpG-
ODNs as in chickens can be divided into two types. The first type evaluated antibody 
response to a protein antigen. This includes administration of BSA, incomplete Freunds 
adjuvant (IFA), and CpG-ODN subcutaneously (SQ) and subsequent measurement of the 
antibody response over thirty-five days (Vleugels et al., 2002). The second type 
evaluated protection from a pathogen. Gomis (Gomis et al., 2003) used CpG-ODNs as 
an immunostimulant to protect from Escherichia coli infections.  Wang et. al. (Wang et 
al., 2003) evaluated the usefulness of CpG-ODNs as an adjuvant to IM DNA vaccination 
against infectious bursal disease virus (IBDV). Recently CpG-ODNs were also used in 
the context of infection with Eimeria acervulina (Dalloul et al., 2004). All three studies 
observed a decrease in pathogenesis when CpG-ODNs were administered I.V. Dalloul 
et. al. (Dalloul et al., 2004) observed no increase in body weight gain when given orally 
before an infectious dose of Eimeria acervulina, nor did they report an increase in 
antibody production. However, a previous study using CT as an oral adjuvant for 
Eimeria tenella or the recombinant antigen 1PE1 observed that antibody levels were 
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increased in the latter but not the former (Girard et al., 1999).Thus, the objective of this 
study was to determine whether a single oral administration of CpG-ODN could alter the 
systemic or mucosal antibody response to BSA when administered to chickens by a 
drinking water route of delivery. 
MATERIALS AND METHODS 
Experimental Animals 
In both Experiment 1 (n=100) and Experiment 2 (n=80), male single comb white 
Leghorn (SCWL) chicks were obtained from a local commercial hatchery (Hyline 
International, College Station, TX) on day of hatch.  All chicks were randomized and 
placed in open floor pens with pine shavings as litter material, at a rearing density of 15 
birds per m2.  Chicks were maintained at age appropriate temperatures and given ad 
libitum access to water and a complete chick starter ration devoid of animal fat, 
formulated to meet or exceed current NRC recommendations for poultry (National 
Research Council, 1994).  
Synthetic CpG-ODN 
 Both CpG-ODN (Gomis et al., 2003) (5’-TCGTCGTTGTCGTTTTGTCGTT-3’) 
and non-CpG-ODN (5’-CTGGTCTTTCTGGTTTTTTTCTGG-3’) were obtained from 
Integrated DNA Technologies, Inc (Coralville, IA).  The ODNs were prepared with a 





 In Experiment 1, day of hatch chicks were divided into four groups; negative 
control, BSA only, BSA with non-CpG-ODN, and BSA with CpG-ODN. At 15 days of 
age, chicks in respective experimental groups received 0.5 ml of 1.4 mg/ml BSA alone, 
0.5 ml of BSA with 75 µg of non-CpG-ODN, or 0.5 ml of BSA with 75 µg CpG-ODN 
orally via syringe and a feeding needle. Care was taken to allow the birds to drink the 
solution as opposed to delivering antigen via bolus delivery. Negative control birds 
received the same volume of water in identical fashion. In Experiment 2 experimental 
groups consisted of chicks receiving 0.5 ml of 1.4 mg/ml BSA with 0, 5, 50, or 100 µg 
of the CpG-ODN, administered as described above. After the initial administration of 
antigen, chicks receiving BSA, in both experiments, were provided with ad libitum 
access to a 1.4 mg/ml BSA solution in bell waterers for six consecutive days, while the 
negative control chicks were provided water in identical fashion. At twenty-six days 
after the first BSA administration all experimental groups in both experiments that 
received BSA were given ad libitum access to the BSA solution for 24 hours as a booster 
immunization. 
Sampling 
 In Experiment 1, five chickens from each experimental group were randomly 
selected at zero, two, five, twelve, nineteen, and thirty-three days post-first 
immunization (dpi). After collecting approximately 1 ml of blood from each animal, all 
chickens were euthanized and the distal ileum, cecal tonsils and distal ceca were 
collected and cultured as described below. In Experiment 2, approximately 1 ml blood 
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was collected from all chickens in each of the four experimental groups on zero, two 
five, twelve, nineteen, twenty-six, and thirty-three dpi. In both experiments, all blood 
was allowed to clot as room temperature, centrifuged, and the serum was transferred to a 
sterile microcentrifuge tube and frozen at –20°C until assayed by ELISA. 
Ex vivo Culture of Intestinal Tissue 
In Experiment 1 only, intestinal specific antibodies to BSA were determined 
according to a previously published ex vivo tissue culture procedure (Zigterman et al., 
1993), with slight modification.  Briefly, after cervical dislocation was performed on 
experimental animals, intestinal tissue samples comprising the distal ileum, cecal tonsil, 
or the distal cecum were removed and immersed in Hank’s balanced salt solution 
(HBSS) containing 500 IU / ml of penicillin and 500 µg/ml of streptomycin. Gut 
contents were removed by flushing with HBSS. The tissues were then cut into segments 
weighing 0.3 g each.  Each intestinal tissue segment was then cut into three smaller 
pieces and further washed with HBSS containing 500 IU / ml of penicillin and 500 
µg/ml of streptomycin. Segments were then suspended in 6 ml of RPMI 1640 
supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml 
gentamicin, and 40 mM Hepes buffer.  The suspensions were centrifuged (5 min, 300 X 
g) and 800 µl aliquots of supernatant (specific for tissue type and respective to 
experimental group) were removed and labeled as time zero (t = 0) samples.  All tissues 
were resuspended in fresh RPMI medium and incubated at 41°C in an environment of 
saturated humidity and 5% CO2 in twelve-well culture plates for 16 hours. Following 16 
h tissue culture, aliquots were removed as described above and marked as time 16 (t=16) 
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samples.  Immunoglobulin levels for intestinal tissue culture media samples were 
determined by indirect ELISA, as described below.  Levels of intestinal specific 
immunoglobulin were determined by subtracting the t=0 absorbance values from t=16 
values.     
Absorption of Cross-reactive Antibodies and Indirect ELISA 
In order to minimize background due to the degree of sequence homology 
between BSA and chicken serum albumin (CSA), an absorption step was performed on 
all samples in experiment one. Serum or media from intestinal cultures were pre-
incubated overnight at 4°C with 40 mg of chicken albumin (Sigma, St. Louis, MO) per 
ml and diluted to 1:320, 1:640 and 1:1280 for serum samples and 1:5, 1:10 and 1:20 for 
intestinal media samples. As pre-immunization samples were taken for Experiment 2 
and a covariate analysis applied in order to control for both bird to bird variation and 
non-specific binding serum from those birds were assayed at the same dilution without 
pre-absorption.  
Indirect ELISA was performed using medium binding flat-bottomed 96 well 
plates (Nalge Nunc International, Rochester, NY). Prior to addition of sample antiserum, 
plates were coated with 5 µg of BSA per well and agitated overnight. Plates were rinsed 
with PBS-T and 150 µl of serum or media was added and agitated for 2 hours. Plates 
were rinsed and 150 µl of horseradish peroxidase (HRPO) conjugated goat anti-chicken 
IgG, IgM, or IgA (Bethyl, Montgomery TX) diluted 1:10,000, was added to the plates 
for an additional hour of incubation. Plates were again rinsed with PBS-T and a substrate 
solution containing 100µl DMSO, 1mg TMB, and 20 µl of H2O2 in 10ml of sodium 
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acetate buffer (pH 5.5) was added.  The reaction was stopped after 15 min by adding 
50µl of 1 M sulfuric acid.  Plates were read in a Sunrise multi-well plate reader (Tecan, 
Austria) at a wavelength of 450 nm. 
Statistical Analysis  
 All samples were run in duplicate.  Absorbance was corrected for plate effect by 
dividing by a positive standard and the mean for each bird was log transformed to 
normalize variance. Experiment 1 data was analyzed using the Univariate General 
Linear Model procedure for Analysis of Variance (SPSS, v. 11.0). Two-way ANOVA 
was performed for each isotype using both day and treatment as factors. In all cases 
there was a significant day*treatment interaction (P<0.01) Therefore each day was 
analyzed for treatment effect using a One-way ANOVA. Statistically different means (P 
< .05) were further separated using Duncan’s Multiple Range Test (SPSS, v. 11.0). 
Experiment two data was analyzed using the Multivariate General Linear Model for 
Analysis of Covariance (SPSS v. 11.0) and means statistically different (P<0.05) from 
the BSA only group were determined using the LSD method (SPSS, v. 11.0). 
RESULTS 
Serum antibody response  
To determine whether CpG-ODNs were stimulatory when administered orally, a 
dose of 75 µg per chick was chosen for Experiment 1. This dose was selected as it was at 
the high end of the stimulatory range reported in previous in vivo experiments. As such it 
was chosen to potentially overcome any presumptive loss of efficacy associated with 
oral administration due to enzymatic degradation within the GI tract.  Data from this 
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initial experiment (Table 3), although indicative of an early increase at 5 dpi, showed no 
differences (P>0.05) in levels among any of the measured isotypes in the serum. By 19 
dpi, differences in levels of IgG, IgM, and IgA (P<0.001, P< 0.05 and P< 0.05, 
respectively) as compared to the negative control and BSA only group were observed. 
On 33 dpi, seven days following the booster immunization, while no differences 
(P>0.05) in IgG and IgA levels between chickens within any groups receiving BSA were 
observed, IgM levels were higher (P<0.05) in chickens within the BSA with CpG group 
as compared to either the negative or BSA alone control groups. Administration of non-
CpG-ODNs resulted in overall lower antibody responses than CpG-ODNs in the serum 
and most often similar to the BSA only group. They were never significantly greater 
than the BSA alone group. 
In Experiment 2, where anti-BSA antibodies were measured in individual 
chickens through 33 dpi, similar data were collected with only a few notable exceptions. 
Again, although there were indications of an early increase by 12 dpi (Figures 1-3), no 
difference (P>0.05) in level among any measured isotypes were observed among the 
experimental groups. By 19 dpi significantly higher (P<0.05) IgG and IgA levels were 
observed for the 50 ug group as compared to BSA alone while IgM levels differed 
(P<0.05) for both the 50 and 100 µg groups. At 26 dpi, the day of booster administration, 
no differences (P>0.05) in IgG levels were observed. In contrast, significantly higher 
IgA and IgM levels were observed for the 5 and 50 µg and 5, 50, and 100 µg groups, 










Day 2 Day 5 Day 12 Day 19 Day 33 
IgG Control 0.01 ± 0.004 0.01 ± 0.001 0.00 ± 0.001B 0.00 ± 0.002C 0.01 ± 0.004C 
 BSA 0.02 ± 0.009 0.03 ± 0.015 0.69 ± 0.093A 0.63 ± 0.061B 0.94 ± 0.011A 
 Non-CpG 0.02 ± 0.008 0.03 ± 0.019 0.46 ± 0.054A 0.73 ± 0.078AB 0.87 ± 0.018B 
 CpG 0.05 ± 0.036 0.14 ± 0.085 0.27 ± 0.120A 0.87 ± 0.062A 0.90 ± 0.034AB 
 
IgM Control 0.00 ± 0.001 0.01 ± 0.002 0.00 ± 0.001b 0.03 ± 0.011c 0.06 ± 0.005c 
 BSA 0.01 ± 0.012 0.01 ± 0.005 0.09 ± 0.023ab 0.16 ± 0.037b 0.12 ± 0.026bc 
 Non-CpG 0.00 ± 0.000 0.02 ± 0.012 0.14 ± 0.040a 0.10 ± 0.008bc 0.19 ± 0.033ab 
 CpG 0.00 ± 0.002 0.14 ± 0.082 0.16 ± 0.046a 0.32 ± 0.080a 0.25 ± 0.068a 
 
IgA Control -0.01 ± 0.001 0.03 ± 0.007 0.00 ± 0.001b -0.02 ± 0.006c -0.02 ± 0.005b 
 BSA 0.00 ± 0.004 0.03 ± 0.010 0.13 ± 0.034a 0.12 ± 0.019b 0.59 ± 0.181a 
 Non-CpG -0.02 ± 0.002 0.04 ± 0.014 0.14 ± 0.019a 0.16 ± 0.027b 0.54 ± 0.101a 
 CpG 0.00 ± 0.005 0.13 ± 0.074 0.14 ± 0.042a 0.35 ± 0.105a 0.61 ± 0.134a 
 
Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  Serum samples were diluted 
1:640, and media from intestinal culture were diluted 1:10.  Means ± S.E. with no common superscript differ 




there were no differences in IgG levels observed, but IgA and IgM levels were again 
significantly (P<0.05) greater for both the 5 and 50 µg CpG groups as compared to the 
BSA control. 
Intestinal Antibody Response 
Intestinal antibody levels from Experiment 1 showed a less pronounced effect 
due to CpG-ODNs administration than those observed in the serum. At 12 dpi, 
significantly higher (P<0.05) IgG levels were observed in the distal ileum (Table 4) for 
the CpG treated group as compared to the negative control group. By 19 dpi, IgG levels 
for all treatment groups differed (P<0.05) from the negative control and persisted 
through day 33 dpi. Differences in IgM levels were observed between the CpG and BSA 
groups (P<0.05), as well as BSA and negative control groups (P<0.05) by 19 dpi. At 33 
dpi, differences in IgM levels were observed in only the CpG and non-CpG groups 
(P<0.05) when compared to the negative control group. Differences in IgA levels 
followed the same general pattern. At 19 dpi differences were observed (P<0.05) for the 
CpG treated group as compared to the BSA and negative control groups, but by 33 dpi 
all treated groups differed from the negative control (P<0.05), but not each other.  
 In the cecal tonsils (Table 5) all treated groups differed (P<0.05) from the 
negative control group by 19 dpi. These differences persisted through 33 dpi for all three 
isotypes. However, despite slight elevations in level for the CpG treated group, none 
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BSA + 5 ug CpG
BSA + 50 ug CpG
BSA + 100 ug CpG
  *
 
Figure 1: Specific serum IgG antibody responses after oral administration of BSA with increasing 
amounts of CpG-ODN. The groups were given 0, 5, 50, or 100 µg of CpG-ODN on day 0. All groups were 
also administered BSA in the drinking water at 1.4 mg/ml on days 0 through 6 as well as on day 26.  Data 
represents mean ± S.E. of peak absorbance values determined by indirect ELISA performed on serum 
samples diluted 1:320. Each point is the mean of 20 birds. Standard errors were calculated per treatment at 
each time point. Means significantly different from the control group (P<0.05) were calculated by the 
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BSA + 50 ug CpG
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Figure 2: Specific serum IgM antibody responses after oral administration of BSA with increasing 
amounts of CpG-ODN. The groups were given 0, 5, 50, or 100  µg of CpG-ODN on day 0. All groups 
were also administered BSA in the drinking water at 1.4 mg/ml on days 0 through 6 as well as on day 26.  
Data represents mean ± S.E. of peak absorbance values determined by indirect ELISA performed on serum 
samples diluted 1:320. Each point is the mean of 20 birds. Standard errors were calculated per treatment at 
each time point. Means significantly different from the control group (P<0.05) were calculated by the 
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BSA + 5 ug CpG
BSA + 50 ug CpG
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Figure 3: Specific serum IgA antibody responses after oral administration of BSA with increasing 
amounts of CpG-ODN. The groups were given 0, 5, 50, or 100  µg of CpG-ODN on day 0. All groups 
were also administered BSA in the drinking water at 1.4 mg/ml on days 0 through 6 as well as on day 26.  
Data represents mean ± S.E. of peak absorbance values determined by indirect ELISA performed on serum 
samples diluted 1:320. Each point is the mean of 20 birds. Standard errors were calculated per treatment at 
each time point. Means significantly different from the control group (P<0.05) were calculated by the 











  In the distal ceca (Table 6) a significant difference (P<0.05) was observed in IgG 
levels between the negative control and the CpG treated group by 12 dpi. At 19 and 33 
dpi IgG levels differed (P<0.05 and P<0.001 respectively) in all treated groups as 
compared to the negative control. Significantly higher (P<0.05) IgM levels were 
observed for the CpG treated group as compared to all others by 19 dpi. By 33 dpi the 
IgM levels in all treated groups differed (P<0.05) from the negative controls, but not 
each other. This trend was also repeated for IgA levels in the ceca, except that at 19 dpi, 
a significantly higher level (P>0.05) for the CpG group was observed as compared to 
both the negative control and non-CpG groups. Overall results for the non-CpG ODN in 
experiment one were lower than for the CpG treated group and most often similar to the 
BSA only group. They were never significantly different from the BSA only group. 
DISCUSSION 
 The use of CpG-ODNs as adjuvants has been studied in a variety of animal 
models including mice, sheep, primates, and chickens (Hartmann et al., 2000; 
McCluskie et al., 2000; Rankin et al., 2001; Vleugels et al., 2002). Studies in chickens 
have, until the present investigation, been limited to intramuscular (IM) or subcutaneous 
(SQ) routes of administration. Using these routes of delivery, CpG-ODNs have been 
demonstrated to increase protection against E. coli infection and increase primary IgG 
and IgM responses to BSA (McCluskie et al., 2000; Vleugels et al., 2002). An optimal 




        TABLE 4: Antibody levels in the distal ileum of chickens orally immunized with BSA with and without CpG-ODN  




Day 2 Day 5 Day 12 Day 19 Day 33 
IgG Control 0.00 ± 0.004 0.00 ±0.001 0.00 ± 0.001b 0.00 ± 0.001b 0.00 ± 0.002b 
 BSA 0.03 ± 0.014 0.00 ± 0.001 0.04 ± 0.008ab 0.16 ± 0.037a 0.34 ± 0.055a 
 Non-CpG 0.01 ± 0.003 0.00 ± 0.001 0.03 ± 0.009ab 0.14 ± 0.023a 0.27 ± 0.057a 
 CpG 0.01 ± 0.004 0.04 ± 0.025 0.09 ± 0.046a 0.26 ± 0.062a 0.33 ± 0.103a 
 
IgM Control 0.00 ± 0.000 0.00 ± 0.001 0.00 ± 0.002 0.00 ± 0.001c 0.00 ± 0.001b 
 BSA 0.00 ± 0.000 0.00 ± 0.002 0.00 ± 0.001 0.01 ± 0.002b 0.01 ± 0.003ab 
 Non-CpG 0.00 ± 0.000 0.00 ± 0.002 0.00 ± 0.001 0.01 ±0.003bc 0.02 ± 0.007a 
 CpG 0.00 ± 0.001 0.01 ± 0.004 0.00 ± 0.002 0.02 ± 0.007a 0.02 ± 0.007a 
 
IgA Control 0.00 ± 0.001 0.00 ± 0.008 0.00 ± 0.004 0.00 ± 0.003C 0.00 ± 0.001b 
 BSA 0.00 ± 0.001 0.00 ± 0.015 0.01 ± 0.005 0.05 ± 0.014B 0.05 ± 0.009a 
 Non-CpG 0.00 ± 0.001 0.00 ± 0.004 0.01 ± 0.003 0.07 ± 0.010AB 0.05 ± 0.011a 
 CpG 0.00 ± 0.002 0.01 ± 0.008 0.00 ± 0.008 0.09 ± 0.013A 0.08 ± 0.022a 
 
         Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  Serum samples were diluted  
         1:640, and media from intestinal culture were diluted 1:10.  Means ± S.E. with no common superscript differ  





        TABLE 5: Antibody levels in the cecal tonsils of chickens orally immunized with BSA with and without CpG-ODN  




Day 2 Day 5 Day 12 Day 19 Day 33 
IgG Control 0.00 ± 0.001 -0.01 ±0.012 0.01 ± 0.003 0.00 ± 0.000b 0.00 ± 0.001b 
 BSA 0.00 ± 0.002 0.00 ± 0.003 0.05 ± 0.028 0.15 ± 0.036a 0.17 ± 0.050a 
 Non-CpG 0.00 ± 0.003 0.02 ± 0.013 0.01 ± 0.015 0.21 ± 0.070a 0.20 ± 0.047a 
 CpG 0.01 ± 0.013 0.01 ± 0.006 0.02 ± 0.013 0.23 ± 0.048a 0.23 ± 0.035a 
 
IgM Control -0.01 ± 0.003 0.00 ± 0.001 0.00 ± 0.001 0.00 ± 0.000b 0.00 ± 0.004b 
 BSA 0.00 ± 0.002 0.00 ± 0.000 0.00 ± 0.001 0.02 ± 0.001a 0.01 ± 0.004a 
 Non-CpG 0.00 ± 0.009 0.00 ± 0.001 0.00 ± 0.003 0.01 ± 0.001a 0.02 ± 0.006a 
 CpG 0.00 ± 0.004 0.00 ± 0.001 0.00 ± 0.002 0.02 ± 0.007a 0.02 ± 0.004a 
 
IgA Control -0.01 ± 0.006 0.00 ± 0.001 0.00 ± 0.000 0.00 ± 0.004b 0.00 ± 0.005b 
 BSA 0.00 ± 0.004 0.00 ± 0.000 0.00 ± 0.000 0.03 ± 0.003a 0.05 ± 0.013a 
 Non-CpG  0.01 ± 0.009 0.00 ± 0.006 0.00 ± 0.000 0.02 ± 0.002a 0.05 ± 0.015a 
 CpG 0.00 ± 0.002 0.00 ± 0.001 0.00 ± 0.001 0.04 ± 0.012a 0.05 ± 0.028a 
 
        Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  Serum samples were diluted 
        1:640, and media from intestinal culture were diluted 1:10.  Means ± S.E. with no common superscript differ  






       TABLE 6: Antibody levels in the ceca of chickens orally immunized with BSA with and without CpG-ODN or a non-  




Day 2 Day 5 Day 12 Day 19 Day 33 
IgG Control 0.00 ± 0.001 0.00 ± 0.001 0.00 ± 0.001b 0.00 ± 0.001b 0.00 ± 0.001B 
 BSA 0.01 ± 0.002 0.01 ± 0.010 0.13 ± 0.050ab 0.20 ± 0.081a 0.39 ± 0.082A 
 Non-CpG 0.02 ± 0.010 0.01 ± 0.002 0.04 ± 0.011b 0.28 ± 0.101a 0.35 ± 0.054A 
 CpG 0.01 ± 0.015 0.03 ± 0.021 0.31 ± 0.146a 0.33 ± 0.074a 0.49 ± 0.062A 
 
IgM Control 0.00 ± 0.005 0.00 ± 0.003 0.00 ± 0.003 0.00 ± 0.001b 0.00 ± 0.001b 
 BSA 0.00 ± 0.003 0.00 ± 0.001 0.01 ± 0.003 0.01 ± 0.002b 0.02 ± 0.004a 
 Non-CpG 0.00 ± 0.001 0.00 ± 0.001 0.00 ± 0.001 0.01 ± 0.003b 0.02 ± 0.007a 
 CpG 0.00 ± 0.003 0.01 ± 0.007 0.01 ± 0.007 0.03 ± 0.010a 0.03 ± 0.006a 
 
IgA Control 0.01 ± 0.003 0.00 ± 0.006 0.01 ± 0.002 0.00 ± 0.002b 0.00 ± 0.004B 
 BSA 0.02 ± 0.005 0.00 ± 0.009 0.01 ± 0.006 0.04 ± 0.012ab 0.13 ± 0.018A 
 Non-CpG 0.02 ± 0.005 0.00 ± 0.006 0.00 ± 0.004 0.02 ± 0.005b 0.09 ± 0.007A 
 CpG 0.00 ± 0.006 0.00 ± 0.006 0.02 ± 0.008 0.07 ± 0.019a 0.08 ± 0.024A 
 
Data represent mean +/- S.E. of peak absorbance values determined by indirect ELISA.  Serum samples were diluted   
1:640, and media from intestinal culture were diluted 1:10.  Means ± S.E. with no common superscript differ 




optimal for humans and mice, respectively. The fact that both motifs demonstrated 
efficacy, and that a wide range of motifs have been shown to induce cytokine and NO 
production (He et al., 2003) as well as lymphocyte proliferation (Rankin et al., 2001) in 
chickens, suggests that different motifs may have dissimilar properties.  
 In this study, we focused on the use of a CpG-ODN as a potential mucosal 
adjuvant. For these experiments, we used a model of oral immunization previously 
demonstrated to be effective by our laboratory and others (Klipper et al., 2000). 
Specifically, we immunized chickens with BSA by adding it to the drinking water for six 
consecutive days and then boosted with antigen in the same manner at day 26. When the 
serum antibody responses of CpG treated birds were compared to those given BSA 
alone, it was generally found that the addition of CpG-ODNs increased the production of 
anti-BSA specific antibodies. IgG was significantly increased on day 19 only, using 50 
and 75 µg of CpG-ODN, but not with 5 or 100 µg. IgM was increased on day 19 with 
50, 75 or 100 µg , on day 26 with 5, 50, and 100 µg, and on day 33 with 50, 75, and 100 
µg.  Serum IgA levels were increased on day 19 for 50 and 75 µg and days 26 and 33 for 
5 and 50 µg. These results, over two experiments, suggest that the oral administration of 
CpG-ODNs increases antibody production in the serum for all isotypes at specific time 
points. Further, it appears to prolong this increase for IgM and IgA dependent upon the 
dose administered. This is in direct contrast to results obtained by injection of CpGs with 
FIA and BSA. That study reported an increase in IgG both pre- and post-boost, an early 
increase in IgM, and no difference in IgA production in the serum (Vleugels et al., 
2002). This distinction demonstrates that the route of the adjuvant administration 
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influences, to some extent, its effects on antibody levels. Since IgA is thought to help 
protect against pathogens that both colonize mucosal surfaces and also those that invade 
via these routes (Lamm, 1997), oral administration could be very important for 
protection against such pathogens.  
 Intestinal responses were also altered by dual administration of both CpG-ODNs 
and BSA, but not to the same extent as in the serum. In the distal ileum, significant 
increases were only observed for IgM and IgA on day 19 as compared to the BSA alone 
group. These increases did not persist beyond the booster immunization in either case. 
Cecal tonsil antibodies showed no difference between CpG treated birds and non-treated 
birds for any isotype. In the cecum the only increase in antibody level was observed for 
IgM on day 19.   
 In conclusion, these experiments suggest that CpG-ODNs can significantly 
enhance antigen-specific humoral responses in the chicken following a single oral dose 
administered early in neonatal life. This route of administration specifically enhances 
both the IgM and IgA responses in the serum, distal ileum and cecum, suggesting this 
route of CpG-ODN administration may be very attractive for generating protection 
against enteric pathogens in commercial poultry.  As oral administration can be extended 
relatively easily to large scale operations, this may be an additional advantage to further 







INVESTIGATION OF POTENTIAL ADJUVANT OR PROPHYLACTIC 
EFFICACY OF CPG-ODNS DURING IMMUNIZATION OR CLINICAL 
CHALLENGE WITH EIMERIA 
INTRODUCTION 
The etiological agents of chicken coccidiosis are a number of Eimeria species 
including, but not limited to, E. acervulina, E. tenella and E. maxima. Each species has 
characteristic prevalence, site of infection and pathogenicity. All species, however, 
parasitize the epithelial cells of the intestinal lining and cause pathological changes 
ranging from local destruction of the mucosa to systemic effects such as blood loss, 
shock, and death (Vermeulen et al., 2001). These changes lead to economic losses 
resulting primarily from decreased performance, such as feed conversion and weight 
gain. In a recent review (Allen and Fetterer, 2002), coccidial infections in poultry were 
estimated to cost the U.S. poultry producing industry in excess of $450 million annually. 
When worldwide production was taken into account, this increased to over $800 million 
per year. While these losses include the cost of prophylactic medication and losses due 
to morbidity, mortality and poor feed conversion, it was further estimated that less than 
20% of these losses were due to prophylaxis, with the other 80% due to decreased 
weight gain and poor feed conversion (Vermeulen et al., 2001).  
 In addition to the current costs due to medications and performance losses, drug-
resistant strains of coccidia are emerging worldwide. Such strains have forced producers 
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to implement elaborate schemes where various coccidiostats (medications) are alternated 
between flocks in an effort to minimize the emergence of drug resistant strains between 
flocks. Even with these precautions being taken, drug-resistant strains continue to 
emerge across the U.S. and the world forcing considerable interest in the development of 
alternative methods of control (Williams, 2002). 
 Live oocysts vaccines are currently the only viable alternative to the use of anti-
coccidial drugs (Chapman et al., 2002). The basis for their use is that after an infection, 
the host is immune to subsequent infections by the same species of Eimeria (Yun et al., 
2000b). This immunity is species specific, therefore vaccines are formulated with 
multiple species. To simulate the manner in which the bird might be exposed to shed 
oocysts following vaccination, researchers have shown that low numbers of parasite 
administered multiple times (trickle immunization) also results in species specific 
protective immunity (Vermeulen et al., 2001). Live vaccines have been used by the 
poultry industry for over 50 years, primarily for broiler breeders and replacement layer 
stock (Chapman et al., 2002). The reluctance to using live vaccines on a broader basis in 
broilers stems from decreased weight gain and feed conversion due to vaccination, when 
compared to performance in medicated birds. The potential for introducing new species 
into the rearing house has also been a detractor (Allen and Fetterer, 2002). While 
improved application methods and attenuated vaccines have led to an increased use in 
broilers (Chapman et al., 2002), an adjuvant capable of offsetting the deleterious effects 
would be advantageous to the poultry industry. 
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 Immunostimulatory DNA sequences (ISS) represent a potential new class of 
mucosal adjuvants.  ISS are DNA sequences containing unmethylated CpG (cytosine-
phosphate-guanosine) dinucleotides in a specific base context, or motif.  They are most 
commonly given in the form of synthetic oligodeoxynucleotides (ODN) made with a 
nuclease resistant phosphorothioate backbone (McCluskie et al., 2000).  Several 
characteristics of CpG-ODNs highlight its potential usefulness as a mucosal adjuvant. 
CpG-ODNs have been reported to stimulate B cells to proliferate, secrete 
immunoglobulins, and secrete IL-6 and IL-12, as well as protect them from undergoing 
apoptosis (Krieg, 2001). Additionally, CpG-ODNs have been shown to enhance 
expression of class II MHC and B7 costimulatory molecules on antigen presenting cells 
(APCs) leading to enhanced antigen presentation to lymphocytes. Activation of 
monocytes, macrophages, and dendritic cells to secrete select cytokines and chemokines 
that increase T-helper functions has also been reported (Krieg, 2002). 
 Research into the effectiveness of CpG-ODNs in chickens can be divided into 
two major types of investigations. The first type evaluated antibody response to a protein 
antigen. This includes administration of BSA, incomplete Freunds adjuvant, and CpG-
ODNs subcutaneously (SQ) and subsequent measurement of the antibody response over 
thirty-five days (Vleugels et al., 2002). Work performed in our laboratory, using oral 
administration of BSA with and without CpG-ODNs, also falls into this category (please 
see Chapter IV of this manuscript). The second type of investigation has evaluated 
protection from a pathogen associated with CpG-ODN administration. Gomis (Gomis et 
al., 2003) used CpG-ODNs as an immunostimulant to protect from Escherichia coli 
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infections.  Wang et. al. (Wang et al., 2003) evaluated the usefulness of CpG-ODNs as 
an adjuvant to IM DNA vaccination against infectious bursal disease virus (IBDV). 
Recently CpG-ODNs were also used to modulate infection with Eimeria acervulina 
(Dalloul et al., 2004). While all three studies observed a decrease in pathogenesis when 
CpG-ODNs were administered I.V., Dalloul et. al. (Dalloul et al., 2004) observed no 
protection related to body weight gain when CpG-ODNs were given orally prior to an 
infectious challenge. As the basis for all currently available vaccines is the repeated 
exposure of low levels of parasite over time (trickle immunization), we evaluated this 
immunostimulatory agent as a potential mucosal adjuvant in this context. Thus, the 
objectives of this study were to investigate the effects of three models of CpG-ODN 
administration on the response to challenge or immunization by two Eimeria species. 
The first objective was to determine whether a single dose of CpG-ODNs given with low 
doses of live parasite could influence body weight gain, lesion score, and feed 
conversion both before and after a clinical Eimeria acervulina challenge. The second 
objective was to determine whether a single dose of CpG-ODNs could influence body 
weight and lesion scores when given simultaneously with a clinical challenge dose of E. 
acervulina or E. tenella. The third objective was to determine whether a single dose of 
CpG-ODNs could influence body weight gain and lesion scores when given one day 






MATERIALS AND METHODS 
Experimental Animals 
 In all experiments male single comb white Leghorn (SCWL) chicks were 
obtained from a local commercial hatchery (Hyline International, Bryan, TX) on day of 
hatch.  All chicks were randomized and placed in Petersime brooder batteries.  Chicks 
were maintained at age appropriate temperatures and given ad libitum access to water 
and a complete chick starter ration formulated to meet or exceed current NRC 
recommendations for poultry (National Research Council, 1994).  
Synthetic CpG-ODN 
 Both CpG-ODNs (Gomis et al., 2003) (5’-TCGTCGTTGTCGTTTTGTCGTT-
3’) and non-CpG-ODNs (5’-CTGGTCTTTCTGGTTTTTTTCTGG-3’) were obtained 
from Integrated DNA Technologies, Inc (Coralville, IA).  The ODNs were prepared with 
a phosphorothioate backbone and reconstituted in pyrogen free PBS immediately before 
administration. 
Parasites 
 Strain #12 of Eimeria acervulina and Strain WLR-1 of Eimeria tenella were 
obtained from Mr. Gary Wilkins and Dr. Mark Jenkins of the Animal Parasite Diseases 
Laboratory (APDL), USDA-ARS, Beltsville MD.  
Experimental Design 
 Trial 1: Trickle Immunization. In all replicates of both experiments, day of 
hatch chicks were divided into six groups; non-immunized / non-challenged control, 
non-immunized / challenged control, immunized / non-challenged, immunized / 
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challenged, CpG-ODN immunized / challenged, and non-CpG-ODN immunized / 
challenged. Beginning on day of hatch, for all replicate trials, all immunized birds were 
given either 500 sporulated oocysts (Experiment 1) or 50 sporulated oocysts 
(Experiment 2) for five consecutive days. CpG-ODN and non-CpG-ODN groups 
received 50 µg of the respective ODN on day of hatch only, with the first administration 
of oocysts. On day 19, all challenged birds were given a single clinical challenge dose of 
1.25 X 105 sporulated oocysts of Eimeria acervulina #12. 
 Trial 2: Simultaneous Administration. In all replicates of all experiments, day of 
hatch chicks were divided into four groups; non-challenged control, challenged control, 
challenged with 50 µg CpG-ODNs or challenged with 50 µg non-CpG-ODNs 
administered simultaneous with challenge. Chickens in Experiment 1 were administered 
ODNs on day 15 along with 1.25 X 105 sporulated oocysts of Eimeria acervulina. 
Chickens in Experiment 2 were given ODNs on day 15 along with 1 X 105 sporulated 
oocysts of E. tenella. 
 Trial 3: Pre-administration. In all replicates of all experiments, day of hatch 
chicks were divided into four groups; non-challenged control, challenged control, 
challenged with 50 µg CpG-ODNs or challenged with 50 µg non-CpG-ODNs 
administered one day prior to challenge. Chickens in Experiment 1 were given ODNs on 
day 14 of life and administered 2 X 105 sporulated oocysts of Eimeria acervulina on day 
15. Chickens in Experiment 2 were given ODNs on day 14 of life and administered 1 X 





 Trial 1: Trickle Immunization. In order to calculate body weight gain and feed 
conversion, all birds were weighed individually on 0, 19, and 25 days post hatch. Body 
weight gain was calculated for each bird on days 19 and 25 post hatch. Feed conversion 
was calculated for each group on days 19 and 25 post hatch, and individual birds were 
lesion scored on day 25 post hatch.  
 Trials 2 and 3: Simultaneous and Pre-administration. In order to calculate body 
weight gain all birds were weighed individually on 0, 15, and 21 days post hatch. Body 
weight gain was calculated and lesions were scored for each bird on day 21 post hatch.  
Statistical Analysis 
 Individual body weight gains and lesion scores were analyzed using the 
Univariate General Linear Model procedure for analysis of variance (SPSS, v. 11.0). 
Statistically different means (P < 0.05) were further separated using Duncan’s Multiple 
Range Test (SPSS, v. 11.0). Due to the experimental design feed conversion was not 
statistically analyzed for trickle immunization. 
RESULTS 
 To determine whether CpG-ODNs could influence body weight gain and feed 
conversion during trickle immunization, or body weight gain and lesion scores after a 
clinical challenge, a dose of 50 µg was chosen. This dose was selected based upon 
antibody responses as determined in previous experiments (please see Chapter IV of this 
manuscript). This dose is also towards the high end of the stimulatory range reported in 
previous in vivo experiments (McCluskie and Davis, 2000) which might alleviate any 
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presumptive loss of efficacy associated with oral administration due to proteolytic 
degradation within the GI tract. During the first set of experiments two Eimeria 
immunization doses were chosen with Experiment 1 evaluating 500 oocysts for five days 
and Experiment 2 evaluating 50 oocysts for five days. These were chosen in order to 
determine whether the immunizing dose would affect the efficacy of CpG-ODNs. In all 
three sets of experiments the clinical challenge dose was determined by performing a 
dose titration and selecting a dose which resulted in an average lesion score of 2 in 
challenged chickens. 
Trial 1: Trickle Immunization 
 Pre-challenge body weight gain. Body weight gain during and subsequent to the 
immunization period for those groups given either CpG-ODNs or non-CpG-ODNs was 
significantly (P<0.001) greater as compared to chickens given the immunizing dose of 
parasite only or those in the non-immunized control group in both replicates of 
Experiment 1 and in one replicate of Experiment 2 (Table 7). In one of two replicates in 
each experiment, the immunized group had significantly (P>0.001) greater weight gain 
than the non-immunized group (Table 7).  
 Pre-challenge feed conversion. Feed conversion ratios followed a contrasting 
pattern in both replicates of both experiments. While we could not test for significance in 
calculated feed conversion ratios, we observed that feed conversion values in ODN 
administered groups were consistently in between the calculated values of non-
immunized controls and those immunized with parasite alone (Table 7). 
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 Post-challenge Body Weight Gain. In Experiment 1 post-challenge body weight 
gain in those birds given CpG-ODNs with the first immunizing dose of parasite was 
significantly greater (P<0.001) than the immunized / non-challenged, non-immunized / 
challenged, and immunized / challenged groups in both replicates (Table 8). However, 
the CpG-ODN administered groups did not differ from the non-CpG-ODN groups in 
either replicate and only differed from the non-immunized / non-challenged group in one 
of two replicates. In Experiment 2 post-challenge body weight gain in those birds given 
CpG-ODNs was significantly greater (P<0.05) than the non-immunized / challenged and 
immunized / challenged groups in both replicates (Table 9). However the CpG-ODN 
administered groups did not differ from the immunized / non-challenged or non-CpG-
ODN groups in either replicate and was greater than (P<0.05) the non-immunized / non-
challenged group in only one of the two replicates (Table 8). 
 Lesion Scores. Lesion scores in Experiment 1 for those birds immunized with 
parasite and CpG-ODNs or non-CpG-ODNs were significantly lower (P<0.001) than 
either the parasite only immunized / challenged and non-immunized / challenged groups 
in both replicates (Table 8). In addition, lesion scores for the ODN immunized birds 
were significantly greater (P<0.001) than both non-challenged groups in only one of two 
replicates. In contrast, no lesions were observed in Experiment 2 for any of the groups 
except the non-immunized / challenged group. While this group did differ significantly 
in replicates 1 and 2 (P<0.001 and P<0.05 respectively), there were no other differences 
among the remaining experimental groups (Table 9).  
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 Post-challenge Feed Conversion. In direct contrast to pre-challenge feed 
conversion, there were no consistent trends observed for post-challenge feed conversion 
(Table9).  
Trial 2: Simultaneous Administration  
 In Experiment 1, CpG-ODNs were given simultaneously with 1.25 X 105 oocysts 
of E. acervulina. No differences were seen between any of the groups with respect to 
weight gain in any of the three replicates (Table 10). There was no decrease in body 
weight gain due to challenge but lesions were observed only in the challenged groups, 
although there were no differences in their severity (Table 10). In Experiment 2 CpG-
ODNs were given with 1.0 X 105 E. tenella oocysts. In replicates one and two, weight 
gain for the non-challenged and challenged only groups differed significantly (P<0.05 
and P<0.001 respectively) from each other, but both the CpG-ODN and non-CpG-ODN 
groups did not differ from the challenge only in either replicate (Table 11). Lesion scores 
differed between the non-challenged and challenged groups, but there were no 
differences related to CpG or non-CpG-ODN administration (Table 11). 
Trial 3: Pre-administration 
  In Experiment 1, although clinical challenge with 2.0 X 105 E. acervulina 
oocysts did result in decreased body weight gain and increased lesion score as compared 
to the non-challenged control, no differences were observed in a single experiment due 
to the administration of CpG-ODNs or non-CpG-ODNs one day prior to challenge 
(Table 12). In Experiment 2, when CpG-ODNs were given twenty-four hours prior to 






TABLE 7: Pre-challenge body weight gain in Experiments 1 and 2 of chickens immunized with 500 or 50 Eimeria acervulina 
oocysts from days 1-5 of life with and without ODNs on day 1 
 
                    Experiment 1 (500 oocysts)                 Experiment 2 (50 oocysts) 
                 Replicate 1                Replicate 2                 Replicate 1            Replicate 2 
 N= BWG Feed 
Conversion
N= BWG Feed 
Conversion













50 95.0 ± 
2.29B 
2.42 30 101.2 
± 
2.70C 





114 98.3 ± 
1.78B 
     2.97 49 99.4 ± 
2.28B 
2.64 29 112.8 
± 
2.42B 








2.93 50 116.5 
± 
2.62A 
2.55 28 127.2 
± 
2.9A 




Data represent mean +/- S.E. of body weight gain for days 1-19 of life. Means ± S.E. within columns with no common 





   TABLE 8:   Post-challenge body weight gain, lesion score and feed conversion in Experiment 1 in chickens  
   immunized with 500 oocysts on days 1-5 of life with and without CpG-ODN or a non-CpG-ODN control on  
   the first  day 
               
        Replicate 1               Replicate 2                     
Group N= BWG LS Feed 
Conversion 




60 73.4 ± 
2.5BC 
0 ± 0D 1.59 25 64.7 ± 
1.5ABC 
0 ± 0C 3.1 
Immunized /  
Non-Challenged 
57 71.5 ± 
1.85C 
0 ± 0D 1.65 24 61.1 ± 
2.28BC 
0 ± 0C 3.08 
Non-Immunized / 
Challenged 




















CpG Immunized  / 
Challenged 




2.00 25 69.9 ± 
4.01A 








1.99 25 69.4 ± 
2.62AB 
0 ± 0C 3.61 
 
    Data represent mean +/- S.E. of body weight gain for days 19 -25 of life or lesion scores on day 25.  
    Means ± S.E. within columns with no common superscript differ significantly at the following levels  







    TABLE 9:   Post-challenge body weight gain, lesion score and feed conversion in Experiment 2 in chickens immunized  
     with 50 oocysts of Eimeria acervulina on days 1-5 of life with and without CpG-ODN or a non-CpG-ODN control on  
     the first day 
 
                  Replicate 1                        Replicate 2 
Group N= BWG LS Feed 
Conversion 






15 67.9 ± 
1.9b 
0 ± 0B 2.60 15 83.1 ± 
2.48A 
0 ± 0B 3.51 
Immunized /  
Non-Challenged 
15 70.9 ± 
1.02ab 
0 ± 0B 3.13 15 73.7 ± 
1.90BC 
0 ± 0B 3.24 
Non-Immunized / 
Challenged 











14 67.3 ± 
2.35b 
0 ± 0B 3.85 14 68.0 ± 
2.80C 
0 ± 0B 3.10 
CpG Immunized  / 
Challenged 
14 75.8 ± 
2.24a 
0 ± 0B 3.44 15 80.9 ± 
2.06AB 
0 ± 0B 2.98 
Non-CpG Immunized / 
Challenged 
14 70.2 ± 
2.98ab 
0 ± 0B 3.10 15 74.3 ± 
3.75ABC 
0 ± 0B 2.45 
 
     Data represent mean +/- S.E. of body weight gain for days 19 -25 of life or lesion scores on day 25.  Means ± S.E. within   





of the challenged groups in either replicate (Table 12). However, a significant (P<0.001) 
improvement of lesion scores was observed in the CpG-ODN administered group as 
compared to the non-CpG-ODN and challenged only groups in both replicates (Table 
12). 
DISCUSSION 
 The use of CpG-ODNs as adjuvants has been studied in a variety of vertebrate 
models including mice, sheep, primates, salmon, and chickens (Bridle et al., 2003; 
Hartmann et al., 2000; McCluskie et al., 2000; Rankin et al., 2001; Vleugels et al., 
2002). Studies in chickens include both in vitro stimulation assays and in vivo protection 
assays. In vitro application of CpG-ODNs has been shown to stimulate lymphocyte 
proliferation, induce nitric oxide (NO) production, and IL-1β mRNA synthesis in the 
HD11 macrophage cell line, induce IFN-γ mRNA expression and nitric oxide production 
in peripheral blood mononuclear cells (PBMCs), and induce degranulation and 
generation of reactive oxygen species (ROS) in heterophils (He et al., 2003; He et al., 
2005; Rankin et al., 2001; Xie et al., 2003).  In vivo studies have investigated CpG-
ODNs adjuvant effects through intramuscular (i.m.), subcutaneous (s.c.), and oral 
administration, and its protection in infectious challenge studies by subcutaneous (s.c.), 
i.m., i.p., intravenous (i.v.), in ovo, and oral administration. Increases in antigen specific 
antibodies were observed when CpG-ODN and BSA were injected subcutaneously both 
with and without incomplete Freund’s adjuvant (IFA) (Vleugels et al., 2002). A modest 
increase was also observed in antigen specific antibodies when both BSA and CpG-
ODNs were given orally (please see Chapter IV of this manuscript). When CpG-ODNs 
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were injected i.m. with a DNA vaccine against infectious bursal disease (IBD), an 
increase in antibody titer, and a decrease in mortalility, morbitity, and lesions were 
observed as compared to vaccine alone animals (Wang et al., 2003). Protective effects of 
CpG-ODNs against bacterial challenges were investigated with Salmonella enteritidis 
when given i.p. and Escherichia coli when given s.q., i.m., and in ovo. In both cases all 
routes provided protection from invasion and mortality (Gomis et al., 2004; Gomis et al., 
2003; He et al., 2005). Protection against protozoan infection has also been investigated. 
Dalloul et. al. (2004) observed that i.v. and s.c., but not oral, administration of CpG-
ODNs could increase body weight gain and decrease oocyst shedding due to subsequent 
infection with Eimeria acervulina. 
The above experiments used motifs optimal for either humans or mice since an 
optimal motif for chickens has yet to be determined. The fact that a wide range of motifs 
have demonstrated efficacy as measured by the ability to induce cytokine and NO 
production, as well as lymphocyte proliferation in chickens, suggests that different 
motifs may have dissimilar properties (He et al., 2003; Rankin et al., 2001). Therefore, a 
study examining the efficacy of different motifs and their influence on immunity to 
Eimeria may be advantageous.  
In the first study, we focused on the use of CpG-ODNs as mucosal adjuvants 
delivered orally with low doses of the protozoan parasite Eimeria acervulina. 
Specifically, we immunized chicks with a subclinical dose (50 or 500 oocysts) for the 
first five days of life both with and without CpG-ODNs or non-CpG-ODNs which was 
  
88
administered with oocysts on the first day of immunization. This was followed with a 
clinical challenge at 19 days of age. Protection was determined by body weight  
gain and feed conversion on days 19 and 25, and lesion development in the intestines on 
day 25. CpG-ODN and non-CpG-ODN immunized chickens had higher body weight 
gains as compared to the immunized alone group in three of four replicate experiments. 
Additionally, feed conversion was consistently in between that of immunized and non-
immunized groups. After clinical challenge, body weight gain was higher in the CpG-
ODN administered groups than the immunized alone groups in both replicates of both 
experiments. However, the CpG-ODN group did not differ from the non-CpG-ODN 
groups in any of the experiments and there were no consistent trends for post-challenge 
feed conversion. 
In the second and third trials in this investigation, we focused on the potential 
protective effects of CpG-ODNs when given either simultaneously with or one day prior 
to a clinically infectious dose of E. acervulina or E. tenella. When CpG-ODNs were 
given simultaneously with an infectious dose of E. acervulina no decrease in body 
weight gain was observed due to challenge. Lesions were observed only in the 
challenged groups although there were no differences in their severity. When CpG-
ODNs were given simultaneously with E. tenella we did observe a decrease in weight 
gain due to challenge as well as lesions in the challenged groups. However, there were 








TABLE 10: Post challenge weight gain and lesion scores in Experiment 1 after co-administration of CpG-ODNs with 
125,000 Eimeria acervulina oocysts 
 
 Replicate 1                          Replicate 2                   Replicate 3 














15 57.2 ± 
2.16 
0 ± 0B 15 57.1 ± 
1.49 
0 ± 0B 15 59.9 ± 
1.69 
0 ± 0B 














15 61.2 ± 
1.96 
1.9 ±  
0.17A 























Data represent mean +/- S.E. of body weight gain for days 15 - 21 of life or lesion scores on day 21. Means ± S.E. within 









       TABLE 11: Post-challenge weight gain and lesions scores in Experiment  
       2 after co-administration of  CpG or non-CpG-ODNs with 100,000  
       Eimeria tenella oocysts 
 
         Replicate 1     Replicate 2 










12 72.5 ± 
2.84a 
0 ± 0B 12 66.7 ± 
2.11a 
0 ± 0B 





























                               Data represent mean +/- S.E. of body weight gain for days 15 - 21 of life or  
       lesion scores on day 21. Means ± S.E. within columns with no common  
       superscript differ  significantly at the following levels of significance: 





   TABLE 12: Post challenge weight gain and lesion scores in Experiment 3 after pre-administration of  
   CpG-ODNs one day before clinical challenge with 200,000 oocysts of Eimeria acervulina or 100,000  
   Eimeria tenella oocysts 
 
Eimeria acervulina            Eimeria tenella        Eimeria tenella  
                 Replicate 1                     Replicate 2 

















0 ± 0B 12 86.43 ± 
4.00a 
0 ± 0C 15 70.6 ± 2.14a 0 ± 0C 












































    Data represent mean +/- S.E. of body weight gain for days 15 - 21 of life or lesion scores on day 21.Means 
     ± S.E. within columns with no common superscript differ significantly at the following levels of significance: 




 When CpG-ODNs were given to chickens one day prior to infectious challenge 
with E. acervulina we did observe a decrease in body weight gain and an increase in 
lesions compared to the non-challenged control group. However, there were no 
differences respective to CpG-ODN or non-CpG-ODN administration. When ODNs 
were given twenty-four hours prior to challenge with E. tenella, we also observed a 
decrease in body weight gain and an increase in lesions due to challenge. While there 
were no differences in weight gain due to CpG-ODN or non-CpG-ODN administration, 
we did observe a reduction in lesions scores in the CpG-ODN administered group as 
compared to the non-CpG-ODN and challenged only groups. 
 These results of the first trial in this study suggest that administration of CpG-
ODNs with an immunizing dose of Eimeria acervulina may improve weight gain and 
feed conversion both before and after subsequent clinical Eimeria challenge. While 
differences between the two immunizing doses were not observed, it is worth noting that 
both doses were well below a clinical challenge dose and also differed from immunizing 
doses used in other experiments (Galmes et al., 1991). Although a previous investigation 
did not report protection from Eimeria acervulina with oral administration of CpG-
ODNs (Dalloul et al., 2004), the first trial used a lower immunizing dose followed by a 
clinical E. acervulina challenge. It is possible that giving a large dose of parasite through 
the same route could abrogate the immunostimulatory effects of the CpG-ODNs, while 
low consistent exposure to the parasite may not. The rational behind this speculation is 
that a low dose of parasite would be less likely to overwhelm the gut mucosa and give 
the CpG-ODNs time to stimulate mucosal immunity.   
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 The results of the second and third trials are in agreement the findings of Dalloul 
et. al. (2004) in that the oral pre-administration of CpG-ODNs does not protect from an 
infectious dose of E. acervulina given twenty-four hours later. However, it was also 
observed that pre-administration of CpG-ODNs can reduce lesion scores, but not 
improve body weight gain, in chickens given a clinical dose of E. tenella twenty-four 
hours later. As a decrease in body weight gain between the challenged only and non-
challenged groups was observed in both experiments the dissimilarity in the results is 
likely due to the species of Eimeria and not the dose given. 
 Although the precise immunostimulatory affects of CpG-ODNs in chickens have 
not been fully defined, in vitro studies have demonstrated that CpG-ODNs can stimulate 
lymphocyte proliferation, induce nitric oxide (NO) production and IL-1β mRNA 
synthesis in the HD11 macrophage cell line, induce IFN-γ mRNA expression and nitric 
oxide production in peripheral blood mononuclear cells (PBMCs), and induce 
degranulation and generation of reactive oxygen species (ROS) in heterophils (He et al., 
2003; He et al., 2005; Rankin et al., 2001; Xie et al., 2003). In addition, differential 
cytokine responses in the duodenum and ceca of chickens infected with E. acervulina or 
E. tenella, suggest that responses to and protection from infection differ between the two 
species (Choi et al., 1999; Laurent et al., 2001).   
 In conclusion, while administration of CpG-ODNs with an immunizing dose of 
Eimeria acervulina may be able to improve weight gain and feed conversion both before 
and after subsequent clinical challenge, neither co-administration nor pre-administration 
of CpG-ODNs with a clinical challenge dose of E. acervulina or E. tenella seems to 
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influence body weight gain. However, while no differences were observed for lesion 
development related to E. acervulina challenge, a significant decrease in lesion score 
due to pre-administration of CpG-ODNs was observed with E. tenella challenge. Taken 
together the above data suggests that orally administered CpG-ODNs may modulate the 
chickens immune response thereby improving performance during vaccination and 
providing either protection from or reduction of immunopathology resulting from E. 
tenella infection. Whether the differences discussed above would be seen in chickens 
capable of more rapid growth is unknown at this time, however given the oral route of 






In Chapter III of this manuscript, antigen specific antibody production to the 
protein antigen BSA was evaluated seven days after administration by one of three 
routes. These were i.p. injection with an alum adjuvant at 12 and 17 days of age, oral 
gavage on 12 through 18 days of age, and drinking water administration on 12 through 
18 days of age. In Experiment 1, serum and bile were assayed for IgG and IgA 
respectively. In Experiment 2, using an ex vivo culture method, the ileum, cecal tonsils, 
and ceca were assayed for both IgG and IgA secretion in addition to measuring serum 
IgG and biliary IgA. In both experiments, drinking water administration and i.p. 
injection resulted in higher serum IgG than oral gavage or the control groups (Tables 1 
and 2). Biliary IgA, however, was only significantly increased in the group administered 
BSA in the drinking water, as compared to gavage, i.p. injection, or the controls (Tables 
1 and 2). When intestinal IgG was measured, both the i.p. injected group and the 
drinking water group had higher levels than oral gavage or the controls (Table 2), 
however there were no differences between the groups with regards to intestinal IgA. 
These observations were interpreted to indicate that purified protein antigen given in the 
drinking water can elicit a primary antigen specific antibody response in the serum, bile, 
and intestine. 
Previous research has established that oral administration of protein in solution is 
immunogenic and not tolerogenic in domestic chickens. (Klipper et al., 2000; Miller and 
Cook, 1994). This has been demonstrated by feeding discrete amounts of solubilized 
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antigen to chickens of an immunocompetent age for six to 14 consecutive days (Klipper 
et al., 2000; Miller and Cook, 1994). Following these regimes, specific antibody 
production has been reported in both the serum and the bile. Alternative approaches of 
antigen administration, such as once a week feedings, do not induce an humoral response 
in the absence of adjuvant (Hoshi et al., 1998; Hoshi et al., 1999).  
The present experiments confirm that oral administration of solubilized BSA 
induces both serum and bile antibody responses and also establishes that a local 
intestinal antibody response is measurable seven days following the last time of 
immunization, indicating specific antibodies were produced by lymphocytes in the distal 
ileum, cecal tonsils, and distal cecum in response to oral BSA immunization. Although 
measured responses consisted primarily of IgG secretion, it bears mentioning that only 
one time point during this evaluation of intestinal antibody secretion was evaluated.  The 
observation that sIgA levels did not differ at seven days after the last immunization, 
where IgG secretions did in fact differ, is not unique. Other studies have reported similar 
findings in response to challenge with Eimeria species or a purified recombinant antigen 
from E. tenella (Girard et al., 1997; Girard et al., 1999).  It is indeed likely that if 
measured at a later day, IgA production may have been elevated in the intestinal sections 
tested, as seen in the studies previously mentioned. 
As stated above, ad libitum, oral administration of solubilized protein antigen 
elicits an immune response in commercial lines of SCWL chickens. While this study 
was limited to SCWL chickens, other studies have reported a similar responsiveness to 
oral BSA administration in broiler chickens (Klipper et al., 2000). When compared to 
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negative controls and crop-gavaged chickens, animals receiving BSA by drinking water 
administration produced higher levels of antigen specific antibodies. It is worthwhile to 
note that IgG levels in those chickens were not significantly different than levels in 
chickens given two i.p. injections of BSA with alum as an adjuvant.  
Observations of drinking water administration being more efficacious in eliciting 
humoral immune responsiveness were also seen by Klipper and co-workers (Klipper et 
al., 2001). One possible explanation may involve crop distention associated with the 
single bolus per os administration.  Crop distention, in this scenario, may likely result in 
the release of proteolytic pepsinogen and HCl by the proventriculus, which might result 
in the degradation of the protein before adequate amounts could reach lymphoid tissue at 
distal sites in the intestine. The findings of Klipper et al. (2000), indicating that feeding 
powdered forms of BSA to mature chicks induced neither an immune response or 
tolerance, and Hoshi et al. (1998) by demonstrating that gavage administration did not 
induce immunity and may induce tolerance, adds support to this speculation. 
Regardless of the mechanisms involved in the observed responsiveness to oral 
antigen in the chicken, the present investigation clearly confirms that solubilized oral 
protein administration induces both systemic and local humoral immune responses. 
These findings suggest that subunit protein vaccines, administered by a drinking water 
route of delivery, may be a feasible option for commercial productions or smaller 
breeder flocks.  While additional investigation into such a route of mass vaccination is 
clearly needed to support such a claim, the ease of administration to large numbers of 
animals by this approach represents a distinct advantage, even more so than what exists 
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for many live and attenuated vaccines for enteric pathogens, which are presently given 
orally. Additional research should also include investigation into variability in 
immunogenicity of antigens isolated from specific pathogens, as well as the level of 
protection induced by these antigens. The duration of immunity elicited by oral protein 
antigen administration with and without adjuvant also needs to be studied. 
In Chapter IV of this manuscript the model developed in Chapter III, oral 
administration of BSA, was used to investigate whether the recently described mucosal 
adjuvant CpG-ODN could influence antibody production to an orally administered 
protein antigen in chickens. In Experiment 1, chickens were divided into four groups. 
These were a negative control, a BSA only group, and groups administered 75 µg of 
either CpG-ODNs or non-CpG-ODNs on the first day of BSA administration only. IgG, 
IgM, and IgA were assayed in the serum and, using the ex vivo culture method 
mentioned above, antibody secretion was measured from the distal ileum, cecal tonsils, 
and cecum. Samples were taken on days 0, 2, 5, 12, 19, and 33 dpi. In Experiment 2 a 
dose effect was investigated and chickens received 0, 5, 50, or 100 µg of CpG-ODN 
administered identically to Experiment 1. Serum was assayed for IgG, IgA and IgM. 
Samples were taken on 0, 2, 5, 12, 19, 26, and 33 dpi. In both experiments a booster 
administration of BSA was given on day 26 dpi. 
Serum levels of BSA specific IgG were greater than the BSA only controls in the 
groups given 50 and 75 µg CpG-ODNs before the boost, but there were no post-boost 
differences (Table 3 and Figure 1). Serum IgM, however, was increased over the BSA 
only control at all levels of CpG-ODNs before the booster administration, and at all 
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levels but 100 µg after the booster (Table3 and Figure 2). Serum IgA was increased over 
the BSA only control at 5 and 50 µg both before and after the boost, but only before the 
boost at 75 µg. In intestinal sections no increase in IgG was observed in any of the 
sections tested, an increase was seen for IgM in both the ileum and ceca before the 
booster, and for IgA in the ileum only, also before the booster. These results suggest that 
the oral administration of CpG ODNs both increases antibody production in the serum 
for all isotypes at specific time points and prolongs this increase for IgM and IgA 
dependent upon the dose. 
 Given the present experiments, CpG-ODNs can significantly enhance antigen-
specific humoral responses in the chicken after a single oral dose administered early in 
neonatal life. In addition, this route of administration specifically enhances both the IgM 
and IgA responses in the serum, distal ileum and cecum, suggesting this route of CpG-
ODN administration may be very attractive for generating protection against enteric 
pathogens in commercial poultry.  As oral administration can be extended relatively 
easily to large scale operations, this may be an additional advantage to further 
development of this strategy for mass vaccination of commercial poultry flocks. 
The use of CpG-ODNs as adjuvants have been studied in a variety of vertebrate 
models including mice, sheep, primates, salmon, and chickens (Bridle et al., 2003; 
Hartmann et al., 2000; McCluskie et al., 2000; Rankin et al., 2001; Vleugels et al., 
2002). Studies in chickens include both in vitro stimulation assays and in vivo protection 
assays. In vitro application of CpG-ODNs has been observed to stimulate lymphocyte 
proliferation, induce nitric oxide (NO) production and IL-1β mRNA synthesis in the 
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HD11 macrophage cell line, induce IFN-γ mRNA expression and nitric oxide production 
in peripheral blood monocytes (PBMCs), and induce degranulation and generation of 
reactive oxygen species (ROS) in heterophils (He et al., 2003; He et al., 2005; Rankin et 
al., 2001; Xie et al., 2003).  In vivo studies have investigated CpG-ODNs adjuvant 
effects through both intramuscular (i.m.) and subcutaneous (s.c.) injections and its 
protective effects by s.c., i.m., i.p., intravenous (i.v.), in ovo, and oral administration. 
Increases in antigen specific antibodies were observed when CpG-ODN and BSA were 
injected subcutaneously both with and without incomplete Freund’s adjuvant (IFA) 
(Vleugels et al., 2002). When CpG-ODNs were injected IM with a DNA vaccines 
against infectious bursal disease (IBD) an increase in antibody titer, and a decrease in 
mortalility, morbitity, and lesions were observed as compared to the vaccine only (Wang 
et al., 2003). The protective effects of CpG-ODNs against bacteria were investigated 
with Salmonella enteritidis when given i.p. and Escherichia coli when given s.q., i.m., 
and in ovo. In both cases all routes provided protection from invasion and mortality 
(Gomis et al., 2004; Gomis et al., 2003; He et al., 2005). Protection against protozoan 
infection has also been investigated. Dalloul et. al. (2000) observed that i.v. and s.q., but 
not oral, administration of CpG-ODNs could increase body weight gain and decrease 
oocyst shedding due to subsequent infection with Eimeria acervulina. 
The above experiments used motifs optimal for either humans or mice, since an 
optimal motif for chickens has not been determined yet. The fact that a wide range of 
motifs have demonstrated efficacy as measured by the ability to induce cytokine and NO 
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production (He et al., 2003) as well as lymphocyte proliferation (Rankin et al., 2001) in 
chickens, suggests that different motifs may have dissimilar properties.  
 In Chapter V, the dose information from Chapter IV was used to investigate the 
adjuvant and protective properties of CpG-ODNs related to Eimeria protection or 
immunity. In order to do this, three administration models were used, all utilizing the 
same dose of CpG-ODNs. The first was to give a single dose of CpG-ODNs with low 
levels of the parasite Eimeria acervulina given over five days (trickle immunization). 
The second was to give the CpG-ODNs simultaneously with a clinically infectious dose 
of either E. acervulina or E. tenella. The third was to give the CpG-ODNs one day 
before a clinically infectious dose of either E. acervulina or E. tenella. 
 In the first study, an immunizing dose of either 50 or 500 oocysts was given for 
the first five days of life both with and without CpG-ODN or non-CpG-ODN 
administration on the first day of immunization. This was followed with a clinical 
challenge at 19 days of age. Protection was determined by body weight gain and feed 
conversion on days 19 and 25, and lesion scores on day 25. CpG-ODN and non-CpG-
ODN immunized chickens had higher body weight gain as compared to the immunized 
alone group in three of four trials (Table 7). Additionally, feed conversion was 
consistently in between that of immunized and non-immunized groups (Table 7). After 
clinical challenge, body weight gain was higher in the CpG-ODN administered groups 
than the immunized alone groups in both replicates of both experiments (Tables 8 and 
9). However, the CpG-ODN group did not differ from the non-CpG-ODN groups in any 
  
102
of the experiments and there were no consistent trends for post-challenge feed 
conversion (Tables 8 and 9). 
 In the second study CpG-ODNs were given either simultaneously with a clinical 
infectious dose of E. acervulina or E. tenella. When CpG-ODNs were given 
simultaneously with an infectious dose of E. acervulina no decrease in body weight gain 
was observed due to challenge (Table 10). Lesions were observed only in the challenged 
groups, although there were no differences in their severity (Table 10). When CpG-
ODNs were given simultaneously with E. tenella we did observe a decrease in weight 
gain due to challenge as well as lesions in the challenged groups. However, there were 
no differences in either due to CpG-ODN or non-CpG-ODN administration (Table 11).  
 When CpG-ODNs were given one day prior to an infectious dose of E. 
acervulina we did observe a decrease in body weight gain and an increase in lesions as 
compared to the non-challenged control (Table 12). However, there were no differences 
with regards to CpG-ODN or non-CpG-ODN administration. When ODNs were given 
twenty-four hours prior to challenge with E. tenella, we also observed a decrease in body 
weight gain and an increase in lesions due to challenge. While there were no differences 
in weight gain due to CpG-ODN or non-CpG-ODN administration, we did observe a 
reduction in lesions scores in the CpG-ODN administered group as compared to the non-
CpG-ODN and challenged only groups (Table 12). 
 These results of the first study suggest that co-administration of CpG-ODNs with 
an immunizing dose of Eimeria acervulina may improve weight gain and feed 
conversion both before and after subsequent clinical challenge. While differences 
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between the two immunizing doses were not observed, it is worth noting that both doses 
were well below a clinical challenge dose and immunizing doses used in other 
experiments (Galmes et al., 1991). Although a previous investigation did not report 
protection from Eimeria acervulina with oral administration of CpG-ODNs (Dalloul et 
al., 2004), the first study used a lower immunizing dose followed by a clinical E. 
acervulina challenge. It is possible that giving a large dose of parasite through the same 
route could abrogate the immunostimulatory effects of the CpG-ODNs, while low 
consistent exposure to the parasite may not. The rational behind this speculation is that a 
low dose of parasite would be less likely to overwhelm the gut mucosa and give the 
CpG-ODNs time to stimulate mucosal immunity.   
 The results of the second and third sets of experiments are in agreement with 
Dalloul et. al. (2004) in that pre-administration of CpG-ODNs orally does not protect 
from an infectious dose of E. acervulina given twenty-four hours later. However, it was 
also observed that pre-administration of CpG-ODNs can reduce lesion scores, but not 
improve body weight gain, in chickens given a clinical dose of E. tenella twenty-four 
hours later. As a decrease in body weight gain between the challenged only and non-
challenged groups was observed in both experiments the dissimilarity in the results is 
likely due to the species and not the dose given. 
 Although the precise immunostimulatory affects of CpG-ODNs in chickens have 
not been fully defined, in vitro studies have demonstrated that CpG-ODNs can stimulate 
lymphocyte proliferation, induce nitric oxide (NO) production and IL-1β mRNA 
synthesis in the HD11 macrophage cell line, induce IFN-γ mRNA expression and nitric 
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oxide production in peripheral blood mononuclear cells (PBMCs), and induce 
degranulation and generation of reactive oxygen species (ROS) in heterophils (He et al., 
2003; He et al., 2005; Rankin et al., 2001; Xie et al., 2003). In addition, differential 
cytokine responses of the duodenum and ceca of chickens infected with E. acervulina or 
E. tenella suggest that responses to and protection from infection differ between the two 
species (Choi et al., 1999; Laurent et al., 2001).   
 In summary, while administration of CpG-ODNs with an immunizing dose of 
Eimeria acervulina may be able to improve weight gain and feed conversion both before 
and after subsequent clinical challenge, neither co-administration nor pre-administration 
of CpG-ODNs with clinical doses of E. acervulina or E. tenella seems to influence body 
weight gain. However, while no differences were observed for lesions scores in E. 
acervulina challenges, a significant decrease in lesion scores due to pre-administration 
of CpG-ODNs was observed with E. tenella challenge. Taken together the above data 
suggest that orally administered CpG-ODNs may modulate the chicken’s immune 
response, thereby improving performance during vaccination and providing either 
protection from or reduction of immunopathology resulting from E. tenella. Whether the 
differences discussed above would be seen in birds capable of more rapid growth is 
unknown at this time, however given the oral route of administration, the use of CpG-
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